https://biolegacyresearch.com/fdas-policy-for-lab-developed-tests-leaves-unanswered-questions/ 2020-12-11T17:34:19+00:00 https://biolegacyresearch.com/fda-offers-guidance-on-safety-info-for-electromagnetic-devices/ 2020-12-11T17:35:38+00:00 https://biolegacyresearch.com/professional-interactions-key-to-fda-inspections-say-former-officials/ 2020-12-11T17:37:18+00:00 https://biolegacyresearch.com/germanys-tuv-sud-issues-first-ivdr-certificate/ 2020-12-11T17:38:45+00:00 https://biolegacyresearch.com/tga-rolls-out-new-regulations-on-personalized-medical-devices/ 2020-12-11T17:40:08+00:00 https://biolegacyresearch.com/medtech-europe-class-d-diagnostics-vulnerable-under-eu-ivdr/ 2020-12-11T17:41:25+00:00 https://biolegacyresearch.com/fda-tells-devicemakers-denied-an-export-permit-how-to-reapply/ 2020-12-11T17:42:56+00:00 https://biolegacyresearch.com/sponsors-of-cid-trials-should-discuss-plans-with-the-fda-guidance-says/ 2020-12-17T05:01:00+00:00 https://biolegacyresearch.com/fda-advisory-panel-gives-big-thumbs-up-for-modernas-covid-19-vaccine/ 2020-12-18T05:01:00+00:00 https://biolegacyresearch.com/eu-to-begin-covid-19-inoculations-with-pfizer-biontech-vaccine-on-dec-27/ 2020-12-18T05:01:00+00:00 https://biolegacyresearch.com/novartis-to-pay-up-to-770-million-for-cadent-therapeutics-enhancing-neuropsychiatric-pipeline/ 2020-12-18T05:01:00+00:00 https://biolegacyresearch.com/sackler-family-current-purdue-ceo-condemned-in-house-oversight-hearing/ 2020-12-18T05:01:00+00:00 https://biolegacyresearch.com/itc-imposes-21-month-u-s-ban-on-botox-competitor-a-reduction-from-initial-ban-of-10-years/ 2020-12-18T05:01:00+00:00 https://biolegacyresearch.com/covid-19-vaccine-developers-adjust-phase-3-trial-protocols-to-allow-authorized-vaccines/ 2020-12-18T05:01:00+00:00 https://biolegacyresearch.com/gsks-benlysta-approved-to-treat-active-lupus-nephritis/ 2020-12-18T05:01:00+00:00 https://biolegacyresearch.com/fda-reviews-pilot-program-on-drug-supply-chain/ 2021-01-05T23:05:19+00:00 https://biolegacyresearch.com/rems-submissions-to-go-all-electronic-within-two-years/ 2021-01-05T23:06:52+00:00 https://biolegacyresearch.com/covid-19-vaccines-under-criminal-threat-agencies-warn/ 2021-01-05T23:08:15+00:00 https://biolegacyresearch.com/florida-drugmaker-hit-for-microbial-contamination/ 2021-01-05T23:10:18+00:00 https://biolegacyresearch.com/fda-limits-controlled-correspondence-options-for-generic-drugmakers/ 2021-01-05T23:12:04+00:00 https://biolegacyresearch.com/483-roundup-fda-raps-four-facilities-for-quality-failures/ 2021-01-05T23:19:49+00:00 https://biolegacyresearch.com/fda-publishes-two-guidance-documents-on-naming-new-drugs/ 2021-01-05T23:21:33+00:00 https://biolegacyresearch.com/eu-clarifies-expectations-for-remote-audits/ 2021-01-07T22:18:23+00:00 https://biolegacyresearch.com/fda-continues-to-target-unapproved-covid-19-tests/ 2021-01-07T22:22:30+00:00 https://biolegacyresearch.com/how-post-brexit-changes-will-impact-devicemakers/ 2021-01-07T22:23:00+00:00 https://biolegacyresearch.com/eu-launches-first-of-six-eudamed-modules/ 2021-01-07T22:25:37+00:00 https://biolegacyresearch.com/483-roundup-inspections-reveal-lapses-at-five-device-facilities/ 2021-01-07T22:27:47+00:00 https://biolegacyresearch.com/fda-recommends-labeling-update-for-laparoscopic-power-morcellators/ 2021-01-07T22:29:18+00:00 https://biolegacyresearch.com/hacked-documents-on-covid-19-vaccines-were-manipulated-ema-says/ 2021-01-19T05:01:00+00:00 https://biolegacyresearch.com/fda-more-selective-about-convening-advisory-committee-panels-during-pandemic/ 2021-01-19T05:01:00+00:00 https://biolegacyresearch.com/report-touts-fdas-actions-in-responding-to-the-pandemic/ 2021-01-19T05:01:00+00:00 https://biolegacyresearch.com/medicare-pays-twice-as-much-as-va-for-many-drugs-gao-finds/ 2021-01-19T05:01:00+00:00 https://biolegacyresearch.com/most-fda-approved-novel-drugs-in-2020-went-through-accelerated-reviews/ 2021-01-19T05:01:00+00:00 https://biolegacyresearch.com/trio-of-drugmakers-file-lawsuits-against-hhs-over-340b-discounts/ 2021-01-19T05:01:00+00:00 https://biolegacyresearch.com/hhs-issues-final-rule-imposing-renewable-term-limits-for-fda-directors/ 2021-01-19T05:01:00+00:00 https://biolegacyresearch.com/moderna-will-evaluate-booster-shot-for-covid-19-vaccine-in-new-trial/ 2021-01-19T05:01:00+00:00 https://biolegacyresearch.com/david-kessler-to-take-reins-as-operation-warp-speeds-scientific-leader/ 2021-01-19T05:01:00+00:00 https://biolegacyresearch.com/cder-hit-most-review-targets-in-2020-despite-pandemic-obstacles/ 2021-02-01T23:06:45+00:00 https://biolegacyresearch.com/cder-planning-multiple-generics-guidances-in-2021-agenda-reveals/ 2021-02-01T23:09:36+00:00 https://biolegacyresearch.com/fda-offers-advice-on-assays-for-covid-19-therapeutic-proteins/ 2021-02-01T23:11:40+00:00 https://biolegacyresearch.com/fda-warns-chinese-otc-drugmaker-for-inadequate-product-testing/ 2021-02-01T23:13:43+00:00 https://biolegacyresearch.com/fda-urges-compounding-firms-to-know-their-api-supplier/ 2021-02-01T23:15:59+00:00 https://biolegacyresearch.com/483-roundup-four-facilities-rapped-for-quality-deficiencies/ 2021-02-01T23:27:09+00:00 https://biolegacyresearch.com/fda-issues-recommendations-for-cell-and-gene-therapy-makers/ 2021-02-01T23:33:34+00:00 https://biolegacyresearch.com/documents-on-covid-19-vaccines-were-manipulated-ema-says/ 2021-02-01T23:38:04+00:00 https://biolegacyresearch.com/fda-to-restructure-generic-drug-office-to-stay-on-top-of-reviews/ 2021-02-01T23:39:44+00:00 https://biolegacyresearch.com/fda-gears-up-to-launch-accreditation-scheme-for-conformity-assessment/ 2021-02-04T21:34:57+00:00 https://biolegacyresearch.com/fda-unveils-action-plan-for-artificial-intelligence-machine-learning-software/ 2021-02-04T21:36:35+00:00 https://biolegacyresearch.com/health-canada-issues-new-guidance-on-postmarket-reports/ 2021-02-04T21:38:29+00:00 https://biolegacyresearch.com/mhra-issues-guidance-on-stand-alone-software/ 2021-02-04T21:40:51+00:00 https://biolegacyresearch.com/repeat-observations-dog-arizona-mask-maker/ 2021-02-04T21:42:31+00:00 https://biolegacyresearch.com/medtronic-hit-for-failing-to-properly-investigate-reports-of-device-failure/ 2021-02-04T21:44:48+00:00 https://biolegacyresearch.com/tga-investigates-covid-19-tests-and-emerging-variants/ 2021-02-04T21:46:17+00:00 https://biolegacyresearch.com/fda-issues-final-guidance-on-new-review-path-for-safer-technologies/ 2021-02-04T21:47:54+00:00 https://biolegacyresearch.com/new-york-contract-manufacturer-hit-for-repeat-observations/ 2021-02-04T21:49:42+00:00 https://biolegacyresearch.com/european-commission-signs-new-supply-deals-with-pfizer-and-moderna/ 2021-02-18T05:01:00+00:00 https://biolegacyresearch.com/woodcock-rebuffs-proposed-firewall-between-fda-staff-following-aducanumab-dispute/ 2021-02-18T05:01:00+00:00 https://biolegacyresearch.com/gsk-and-vir-biotechnology-expand-monoclonal-antibody-partnership/ 2021-02-18T05:01:00+00:00 https://biolegacyresearch.com/eu-launches-vaccine-incubator-to-take-on-coronavirus-variants/ 2021-02-18T05:01:00+00:00 https://biolegacyresearch.com/report-shows-7-9-percent-of-drugs-ultimately-won-regulatory-approval-over-last-decade/ 2021-02-18T05:01:00+00:00 https://biolegacyresearch.com/zients-fronts-biden-administrations-restructured-operation-warp-speed/ 2021-02-18T05:01:00+00:00 https://biolegacyresearch.com/uk-to-start-worlds-first-covid-19-human-challenge-trial/ 2021-02-18T05:01:00+00:00 https://biolegacyresearch.com/new-initial-question-coming-soon-to-fda-adverse-event-reporting-system/ 2021-03-01T22:03:18+00:00 https://biolegacyresearch.com/fresenius-kabis-cancer-drug-subsidiary-pleads-guilty-to-destroying-records/ 2021-03-01T22:05:35+00:00 https://biolegacyresearch.com/acelrx-pharmaceuticals-draws-warning-letter-for-misleading-claims/ 2021-03-01T22:08:14+00:00 https://biolegacyresearch.com/fda-warns-florida-manufacturer-over-quality-validation-concerns/ 2021-03-01T22:10:09+00:00 https://biolegacyresearch.com/vaccine-developers-face-challenges-in-scaling-up-manufacturing/ 2021-03-01T22:12:04+00:00 https://biolegacyresearch.com/alembic-pharmaceuticals-draws-form-483-over-five-quality-observations/ 2021-03-01T22:14:58+00:00 https://biolegacyresearch.com/cder-outlines-its-drug-safety-priorities-during-the-pandemic/ 2021-03-01T22:17:08+00:00 https://biolegacyresearch.com/fda-drug-recalls-rise-in-2020-new-report-says/ 2021-03-01T22:19:28+00:00 https://biolegacyresearch.com/fda-preparing-guidance-on-compounding-pandemic-drugs/ 2021-03-01T22:21:05+00:00 https://biolegacyresearch.com/new-postmarket-surveillance-tool-for-covid-19-vaccines-being-used/ 2021-03-01T22:22:31+00:00 https://biolegacyresearch.com/ec-agrees-on-common-list-of-covid-19-rapid-antigen-tests/ 2021-03-04T21:50:32+00:00 https://biolegacyresearch.com/new-postmarket-surveillance-tool-for-covid-19-vaccines/ 2021-03-04T21:53:00+00:00 https://biolegacyresearch.com/fda-appoints-kevin-fu-as-first-medical-device-cybersecurity-chief/ 2021-03-04T21:55:17+00:00 https://biolegacyresearch.com/fdas-device-center-has-covid-test-regrets/ 2021-03-04T21:57:00+00:00 https://biolegacyresearch.com/ec-details-how-legacy-devices-will-be-managed-in-eudamed/ 2021-03-04T22:00:22+00:00 https://biolegacyresearch.com/new-mdr-notified-body-designated-in-finland/ 2021-03-04T22:02:08+00:00 https://biolegacyresearch.com/tga-issues-guidance-on-clinical-decision-support-software/ 2021-03-04T22:03:57+00:00 https://biolegacyresearch.com/report-cder-is-meeting-user-fee-goals-but-struggling-with-biosimilar-application-targets/ 2021-03-19T04:01:00+00:00 https://biolegacyresearch.com/emas-blood-clot-investigation-finds-astrazenecas-covid-19-vaccine-still-safe-and-effective/ 2021-03-19T04:01:00+00:00 https://biolegacyresearch.com/senate-confirms-xavier-becerra-as-hhs-secretary/ 2021-03-19T04:01:00+00:00 https://biolegacyresearch.com/fdas-peter-marks-testifies-about-updating-vaccines-to-address-covid-19-variants/ 2021-03-19T04:01:00+00:00 https://biolegacyresearch.com/ond-managed-a-slew-of-euas-a-reorg-pdufa-goals-and-regular-business-during-pandemic-says-annual-report/ 2021-03-19T04:01:00+00:00 https://biolegacyresearch.com/u-s-will-send-4-million-astrazeneca-vaccine-doses-to-canada-and-mexico/ 2021-03-19T04:01:00+00:00 https://biolegacyresearch.com/nice-issues-another-no-to-mercks-keytruda-for-advanced-bladder-cancer/ 2021-03-19T04:01:00+00:00 https://biolegacyresearch.com/drug-price-negotiating-muscle-for-medicare-likely-to-be-modest-in-final-spending-bill/ 2021-10-26T04:01:00+00:00 https://biolegacyresearch.com/mercks-oral-pill-for-hiv-shows-efficacy-in-two-trials/ 2021-10-26T04:01:00+00:00 https://biolegacyresearch.com/novartis-canakinumab-just-cant-get-the-magic-back/ 2021-10-26T04:01:00+00:00 https://biolegacyresearch.com/astrazeneca-continues-its-hit-parade-with-yet-another-imfinzi-win/ 2021-10-26T04:01:00+00:00 https://biolegacyresearch.com/eli-lilly-seeks-fda-approval-for-experimental-alzheimers-drug/ 2021-10-26T19:03:55+00:00 https://biolegacyresearch.com/modernas-interim-data-on-kids-age-6-to-12-shows-strong-vaccine-effectiveness/ 2021-10-26T20:01:00+00:00 https://biolegacyresearch.com/fda-lags-far-behind-ema-health-canada-in-proactively-releasing-drug-data/ 2021-10-26T21:45:00+00:00 https://biolegacyresearch.com/fda-denies-petition-to-pull-euas-for-moderna-jj-covid-19-vaccines/ 2021-10-26T22:16:46+00:00 https://biolegacyresearch.com/expert-panel-recommends-authorization-of-pfizers-covid-19-vaccine-for-kids-aged-5-11/ 2021-10-26T22:37:57+00:00 https://biolegacyresearch.com/biden-administration-may-nominate-new-fda-commissioner-as-soon-as-next-week/ 2021-10-27T21:30:38+00:00 https://biolegacyresearch.com/jj-agrees-to-pay-297-million-to-resolve-texas-opioid-lawsuits/ 2021-10-27T21:33:16+00:00 https://biolegacyresearch.com/merck-agrees-to-license-its-antiviral-pill-to-medicines-patent-pool/ 2021-10-27T21:50:00+00:00 https://biolegacyresearch.com/empower-pharmacy-hit-with-multiple-infraction-warning-letter/ 2021-10-27T21:52:00+00:00 https://biolegacyresearch.com/white-house-pulls-drug-pricing-reform-from-scaled-down-spending-package/ 2021-10-28T22:24:58+00:00 https://biolegacyresearch.com/antidepressant-cuts-covid-19-hospitalizations-by-up-to-73-percent/ 2021-10-28T22:25:50+00:00 https://biolegacyresearch.com/fda-nih-drugmakers-and-nonprofits-launch-gene-therapy-consortium-for-rare-diseases/ 2021-10-28T22:26:52+00:00 https://biolegacyresearch.com/novartis-hit-with-subpoena-from-doj-over-marketing-and-pricing-of-heart-drug-entresto/ 2021-10-28T22:27:59+00:00 https://biolegacyresearch.com/fda-seeks-feedback-on-research-plan-on-targeted-mechanism-of-action-ads/ 2021-10-28T22:29:09+00:00 https://biolegacyresearch.com/takeda-strengthens-its-car-t-platform-with-gammadelta-therapeutics-acquisition/ 2021-10-28T22:30:13+00:00 https://biolegacyresearch.com/fda-dings-sesen-bio-for-misconduct-by-study-investigator/ 2021-10-28T22:31:38+00:00 https://biolegacyresearch.com/fda-releases-gdufa-iii-commitment-letter/ 2021-11-01T04:01:00+00:00 https://biolegacyresearch.com/fda-could-get-300-million-for-infrastructure-in-build-back-better-package/ 2021-11-01T04:01:00+00:00 https://biolegacyresearch.com/fda-posts-final-guidance-on-submitting-reports-of-number-of-drugs-distributed/ 2021-11-01T04:01:00+00:00 https://biolegacyresearch.com/democrats-make-last-ditch-effort-to-include-drug-pricing-reform-in-spending-bill/ 2021-11-01T04:01:00+00:00 https://biolegacyresearch.com/cortexyme-bets-on-p-gingivalis-toxin-disrupter-to-slow-alzheimers-progression/ 2021-11-01T04:01:00+00:00 https://biolegacyresearch.com/fda-authorizes-pfizer-biontech-covid-19-shot-for-children/ 2021-11-01T04:01:00+00:00 https://biolegacyresearch.com/fda-issues-guidance-on-microbiological-contamination-after-many-adverse-events/ 2021-11-01T19:00:56+00:00 https://biolegacyresearch.com/trade-group-asks-for-changes-to-fda-guidance-on-ich-q12-in-public-comment/ 2021-11-01T19:03:29+00:00 https://biolegacyresearch.com/warning-letter-roundup-four-drug-facilities-draw-warnings-for-gmps/ 2021-11-01T19:06:18+00:00 https://biolegacyresearch.com/483-roundup-fda-raps-four-firms-for-quality-deficiencies/ 2021-11-01T19:08:31+00:00 https://biolegacyresearch.com/teva-pharmaceutical-halts-drug-production-at-irvine-calif-plant/ 2021-11-01T19:10:15+00:00 https://biolegacyresearch.com/house-passes-bill-to-promote-continuous-drug-manufacturing/ 2021-11-01T19:13:07+00:00 https://biolegacyresearch.com/fda-releases-guidance-on-ich-q13-continuous-manufacturing-concepts/ 2021-11-01T19:14:33+00:00 https://biolegacyresearch.com/united-therapeutics-draws-crl-for-drug-device-combination/ 2021-11-01T19:16:00+00:00 https://biolegacyresearch.com/eli-lilly-prevails-in-suit-against-hhs-over-340b-drug-price-program/ 2021-11-02T04:01:00+00:00 https://biolegacyresearch.com/jj-covid-19-vaccine-linked-to-increase-in-rare-brain-blood-clots/ 2021-11-02T04:01:00+00:00 https://biolegacyresearch.com/merck-inks-deal-with-synthekine-to-develop-novel-cytokine-therapeutics-delays-deal-to-acquire-acceleron/ 2021-11-02T04:01:00+00:00 https://biolegacyresearch.com/jj-settles-thousands-of-risperdal-cases-says-sec-filing/ 2021-11-02T04:01:00+00:00 https://biolegacyresearch.com/fda-delays-authorizing-moderna-covid-19-shot-in-adolescents/ 2021-11-02T04:01:00+00:00 https://biolegacyresearch.com/fda-launches-nextgen-portal-for-reporting-volume-data-on-drugs-and-biologics/ 2021-11-02T04:01:00+00:00 https://biolegacyresearch.com/fda-gets-favorable-response-on-bsufa-iii-commitments/ 2021-11-02T21:27:00+00:00 https://biolegacyresearch.com/democrats-reach-deal-on-including-drug-pricing-reform-in-build-back-better/ 2021-11-02T21:49:00+00:00 https://biolegacyresearch.com/california-judge-sides-with-drugmakers-in-opioid-abuse-lawsuit/ 2021-11-02T21:50:40+00:00 https://biolegacyresearch.com/cdc-expert-panel-backs-pfizer-covid-19-vaccine-for-young-kids/ 2021-11-02T22:47:25+00:00 https://biolegacyresearch.com/gao-critiques-fda-oversight-of-vaccine-manufacturing/ 2021-11-02T22:50:26+00:00 https://biolegacyresearch.com/pfizer-quietly-offers-warranty-on-nsclc-drug-xalkori-should-it-fail-to-show-benefit/ 2021-11-04T04:01:00+00:00 https://biolegacyresearch.com/bayer-invests-in-gro-biosciences-pioneering-protein-therapeutics-efforts/ 2021-11-04T04:01:00+00:00 https://biolegacyresearch.com/fda-slaps-spartan-chemical-over-microbial-testing-quality-issues/ 2021-11-04T04:01:00+00:00 https://biolegacyresearch.com/novartis-partners-with-dunad-therapeutics-to-develop-protein-degradation-therapies/ 2021-11-04T04:01:00+00:00 https://biolegacyresearch.com/mercks-and-ridgebacks-oral-treatment-for-covid-19-gets-its-first-regulatory-approval/ 2021-11-05T04:01:00+00:00 https://biolegacyresearch.com/updated-build-back-better-bill-has-scaled-down-drug-pricing-provisions/ 2021-11-05T04:01:00+00:00 https://biolegacyresearch.com/two-bespoke-car-t-regimens-shine-for-refractory-b-cell-lymphoma/ 2021-11-05T04:01:00+00:00 https://biolegacyresearch.com/intranasal-carbetocin-fails-to-win-over-fda-advisory-committee/ 2021-11-05T04:01:00+00:00 https://biolegacyresearch.com/novartis-to-sell-its-one-third-voting-stake-in-roche-back-to-roche-for-almost-21b/ 2021-11-05T04:01:00+00:00 https://biolegacyresearch.com/house-delays-vote-on-build-back-better-bill-with-scaled-down-drug-pricing-reform/ 2021-11-05T22:15:02+00:00 https://biolegacyresearch.com/pfizers-combo-covid-19-pill-reduced-risk-of-hospitalization-death/ 2021-11-05T22:16:06+00:00 https://biolegacyresearch.com/the-federal-governments-600m-contract-with-troubled-vaccine-manufacturing-plant-emergent-is-no-more/ 2021-11-05T22:17:11+00:00 https://biolegacyresearch.com/the-u-s-has-a-booming-and-dangerous-off-the-books-stem-cell-business/ 2021-11-05T22:18:08+00:00 https://biolegacyresearch.com/fda-observes-lapses-in-lot-failure-investigations-at-miyoshi-america/ 2021-11-05T22:19:00+00:00 https://biolegacyresearch.com/two-federal-judges-render-opposite-rulings-in-340b-cases-making-matters-murkier/ 2021-11-08T20:35:14+00:00 https://biolegacyresearch.com/indian-generics-maker-settles-with-plaintiffs-in-u-s-price-fixing-case/ 2021-11-08T20:37:04+00:00 https://biolegacyresearch.com/regenerons-covid-19-antibody-cocktail-shows-8-month-preventative-protection/ 2021-11-08T20:39:13+00:00 https://biolegacyresearch.com/liquidia-scores-tentative-ok-for-dry-powder-inhaled-treprostinil/ 2021-11-08T20:47:00+00:00 https://biolegacyresearch.com/gsk-touts-positive-phase-3-data-for-anemia-linked-ckd-drug/ 2021-11-08T20:48:58+00:00 https://biolegacyresearch.com/bristol-myers-squibb-teases-positive-phase-3-data-for-opdivo-in-nsclc/ 2021-11-08T20:52:00+00:00 https://biolegacyresearch.com/jj-wins-465-million-opioid-verdict-reversal-in-oklahoma/ 2021-11-09T23:10:21+00:00 https://biolegacyresearch.com/fda-releases-almost-50-product-specific-guidances-to-aid-generics-makers/ 2021-11-09T23:13:59+00:00 https://biolegacyresearch.com/biogen-investigating-death-related-to-brain-swelling-in-aducanumab-patient/ 2021-11-09T23:15:03+00:00 https://biolegacyresearch.com/pfizer-biontech-file-for-updated-eua-allowing-covid-19-boosters-in-all-adults/ 2021-11-09T23:16:00+00:00 https://biolegacyresearch.com/ranked-hospitals-charge-insurance-companies-and-out-of-pocket-patients-exponentially-more-than-medicare/ 2021-11-09T23:25:55+00:00 https://biolegacyresearch.com/study-suggests-covis-pharmas-preterm-birth-drug-carries-cancer-risk/ 2021-11-09T23:26:58+00:00 https://biolegacyresearch.com/moderna-and-nih-dig-in-over-covid-19-vaccine-patent-dispute/ 2021-11-11T05:01:00+00:00 https://biolegacyresearch.com/fda-gives-inovio-green-light-for-phase-3-trial-of-dna-covid-19-vaccine/ 2021-11-11T05:01:00+00:00 https://biolegacyresearch.com/ctdna-could-become-an-early-endpoint-in-oncology-says-nonprofit-research-group/ 2021-11-11T05:01:00+00:00 https://biolegacyresearch.com/astrazeneca-to-create-distinct-vaccine-and-antibodies-business/ 2021-11-11T05:01:00+00:00 https://biolegacyresearch.com/new-registry-will-track-real-world-efficacy-of-approved-alzheimers-treatments/ 2021-11-11T05:01:00+00:00 https://biolegacyresearch.com/automated-systems-that-extract-data-from-ehrs-would-help-fda-study-antibiotic-resistant-bacteria/ 2021-11-11T05:01:00+00:00 https://biolegacyresearch.com/eu-adds-rare-spinal-condition-to-jj-covid-19-side-effects/ 2021-11-11T22:10:00+00:00 https://biolegacyresearch.com/eisai-biogen-get-some-lecanemab-exposure/ 2021-11-11T22:11:14+00:00 https://biolegacyresearch.com/ema-endorses-covid-19-antibody-therapies-from-regeneron-roche-celltrion/ 2021-11-11T22:12:16+00:00 https://biolegacyresearch.com/current-dosing-of-oncology-drugs-is-unnecessarily-high-and-needs-revision-says-report/ 2021-11-11T22:13:14+00:00 https://biolegacyresearch.com/alzheimers-drugs-should-be-no-more-than-3000-per-year-to-be-cost-effective-study-says/ 2021-11-11T23:58:47+00:00 https://biolegacyresearch.com/researchers-question-value-of-confirmatory-trials-under-accelerated-approval/ 2021-11-12T00:00:23+00:00 https://biolegacyresearch.com/uks-nice-rejects-biomarins-drug-for-ultra-rare-metabolic-disorder/ 2021-11-15T05:01:00+00:00 https://biolegacyresearch.com/moderna-defends-against-myocarditis-fears-in-conference-call/ 2021-11-15T05:01:00+00:00 https://biolegacyresearch.com/biden-announces-plan-to-nominate-robert-califf-as-fda-commissioner/ 2021-11-15T05:01:00+00:00 https://biolegacyresearch.com/emas-chmp-recommends-11-new-treatments-at-monthly-meeting/ 2021-11-15T05:01:00+00:00 https://biolegacyresearch.com/jj-to-separate-prescription-drugs-business-from-otc-consumer-products/ 2021-11-15T05:01:00+00:00 https://biolegacyresearch.com/fda-should-get-far-more-aggressive-about-clinical-trial-reporting-study-says/ 2021-11-15T22:09:09+00:00 https://biolegacyresearch.com/judge-says-case-against-merck-over-shingles-vaccine-may-proceed/ 2021-11-15T22:10:22+00:00 https://biolegacyresearch.com/ftc-approves-confidential-changes-to-bms-divestiture-agreements-related-to-otezla/ 2021-11-15T22:11:40+00:00 https://biolegacyresearch.com/aduhelm-is-pushing-up-medicare-premiums-even-before-cms-makes-its-payment-decision/ 2021-11-15T22:13:05+00:00 https://biolegacyresearch.com/trial-of-opioid-distributors-gets-underway-in-washington-state/ 2021-11-15T22:28:48+00:00 https://biolegacyresearch.com/fda-got-creative-with-inspections-during-pandemic-plans-to-stay-that-way/ 2021-11-16T23:03:13+00:00 https://biolegacyresearch.com/pfizer-applies-for-eua-for-its-oral-covid-19-treatment-inks-deal-with-medicines-patent-pool/ 2021-11-16T23:05:23+00:00 https://biolegacyresearch.com/abbvies-humira-six-other-drugs-saw-unsupported-price-hikes-in-2020-icer-says/ 2021-11-16T23:07:42+00:00 https://biolegacyresearch.com/house-hopes-to-vote-on-build-back-better-act-by-friday/ 2021-11-16T23:41:00+00:00 https://biolegacyresearch.com/bill-introduced-to-update-the-21st-century-cures-act-new-research-agency-proposed/ 2021-11-17T22:35:51+00:00 https://biolegacyresearch.com/despite-summer-launch-questions-remain-about-fdas-inspectional-affairs-council/ 2021-11-17T23:39:44+00:00 https://biolegacyresearch.com/fda-used-new-tools-to-ensure-regulatory-compliance-in-2020-2021/ 2021-11-17T23:41:14+00:00 https://biolegacyresearch.com/for-europe-aduhelm-is-probably-a-no-go/ 2021-11-18T05:01:00+00:00 https://biolegacyresearch.com/federal-judge-approves-345-million-epipen-settlement-by-pfizer/ 2021-11-18T21:35:13+00:00 https://biolegacyresearch.com/novo-nordisk-to-acquire-dicerna-for-3-3-billion-netting-platform-for-targeting-disease-causing-genes/ 2021-11-18T21:36:41+00:00 https://biolegacyresearch.com/astrazenecas-dual-antibody-injection-cuts-risk-of-covid-19-infection/ 2021-11-18T21:40:50+00:00 https://biolegacyresearch.com/pfizer-inks-5-29-billion-pact-with-u-s-to-supply-covid-19-antiviral/ 2021-11-18T22:21:52+00:00 https://biolegacyresearch.com/fda-slaps-indiana-compounder-over-sterile-drug-lapses/ 2021-11-18T22:35:34+00:00 https://biolegacyresearch.com/house-expected-to-pass-build-back-better-act-with-lightweight-drug-pricing-reform/ 2021-11-19T03:45:52+00:00 https://biolegacyresearch.com/cdc-expert-panel-endorses-pfizer-moderna-boosters-for-all-adults/ 2021-11-19T05:01:00+00:00 https://biolegacyresearch.com/immune-cell-decreases-halt-mercks-dual-agent-antiretroviral-hiv-study/ 2021-11-22T05:01:00+00:00 https://biolegacyresearch.com/chinese-api-maker-that-sparked-global-controversy-over-impurity-laden-heart-drugs-gets-a-close-out-of-its-fda-warning-letter/ 2021-11-22T05:01:00+00:00 https://biolegacyresearch.com/nice-oks-injectable-hiv-drug-and-gives-conditional-approval-to-sma-therapy/ 2021-11-22T05:01:00+00:00 https://biolegacyresearch.com/gao-shines-spotlight-on-dearth-of-antibacterial-and-antifungal-treatments-despite-special-pathway-available-to-developers/ 2021-11-22T05:01:00+00:00 https://biolegacyresearch.com/house-passes-build-back-better-act-with-drug-pricing-provisions-intact/ 2021-11-22T05:01:00+00:00 https://biolegacyresearch.com/advocacy-group-pushes-fda-to-disqualify-minneapolis-irb-investigators-from-running-trials/ 2021-11-23T05:01:00+00:00 https://biolegacyresearch.com/dercher-enterprises-hit-with-fourth-483-in-13-years-new-quality-director-works-to-overhaul-processes/ 2021-11-23T05:01:00+00:00 https://biolegacyresearch.com/indian-generics-maker-sun-pharma-recalls-ed-meds-in-the-u-s/ 2021-11-23T05:01:00+00:00 https://biolegacyresearch.com/pfizer-says-its-covid-19-vaccine-is-100-percent-effective-in-kids-12-15/ 2021-11-23T05:01:00+00:00 https://biolegacyresearch.com/fda-completes-more-inspections-than-anticipated-in-fiscal-2021/ 2021-11-23T05:01:00+00:00 https://biolegacyresearch.com/about-40-percent-of-aduhelm-patients-experienced-brain-swelling-bleeds/ 2021-11-23T20:43:12+00:00 https://biolegacyresearch.com/new-emails-suggest-former-fda-commissioner-hahn-intentionally-made-false-claim-about-convalescent-plasma/ 2021-11-23T20:45:33+00:00 https://biolegacyresearch.com/japanese-sterile-drugmaker-toyobo-hit-with-11-observation-483/ 2021-11-23T20:47:00+00:00 https://biolegacyresearch.com/gsk-to-license-arrowheads-rnai-therapeutic-for-liver-disease-in-1-billion-deal/ 2021-11-23T21:47:06+00:00 https://biolegacyresearch.com/biden-administration-misses-key-deadline-likely-pushing-califf-nomination-vote-into-2022/ 2021-11-24T22:44:39+00:00 https://biolegacyresearch.com/more-cities-counties-may-sue-pharmacy-companies-over-opioids-now-that-two-ohio-counties-have-prevailed/ 2021-11-24T22:45:47+00:00 https://biolegacyresearch.com/europe-concedes-intellectual-property-waivers-can-help-fight-covid-19/ 2021-11-24T22:46:59+00:00 https://biolegacyresearch.com/bharat-biotechs-covaxin-was-50-percent-effective-in-real-world-study/ 2021-11-24T22:47:52+00:00 https://biolegacyresearch.com/u-s-based-covid-19-vaccine-makers-are-gearing-up-to-face-omicron-with-biden-administrations-help/ 2021-11-29T21:22:02+00:00 https://biolegacyresearch.com/ocugen-hits-a-stumbling-block-for-its-covid-19-vaccine-candidate/ 2021-11-29T21:23:48+00:00 https://biolegacyresearch.com/u-s-trade-rep-will-press-wto-for-ip-framework-for-covid-19-vaccines-despite-meeting-postponement/ 2021-11-29T22:18:00+00:00 https://biolegacyresearch.com/fda-panel-reviews-data-showing-mercks-covid-19-antiviral-reduces-hospitalization-by-30-percent/ 2021-11-29T22:22:00+00:00 https://biolegacyresearch.com/fda-offers-advice-on-using-real-world-evidence-from-registries/ 2021-11-29T23:12:57+00:00 https://biolegacyresearch.com/immunogen-will-file-bla-for-mirvetuximab-in-hard-to-treat-ovarian-cancer/ 2021-12-01T05:01:00+00:00 https://biolegacyresearch.com/house-to-vote-on-budget-continuing-resolution-as-early-as-wednesday/ 2021-12-01T05:01:00+00:00 https://biolegacyresearch.com/gsk-hires-vaccine-star-away-from-pfizer-to-boost-its-vaccine-operations/ 2021-12-01T05:01:00+00:00 https://biolegacyresearch.com/fda-signals-willingness-to-quickly-collaborate-with-industry-to-tackle-omicron/ 2021-12-01T05:01:00+00:00 https://biolegacyresearch.com/fda-panel-narrowly-backs-eua-for-mercks-covid-19-antiviral/ 2021-12-01T05:01:00+00:00 https://biolegacyresearch.com/house-vote-on-continuing-resolution-in-jeopardy-ahead-of-friday-deadline/ 2021-12-02T05:01:00+00:00 https://biolegacyresearch.com/biogen-loses-its-appeal-to-revive-tecfidera-patent/ 2021-12-02T05:01:00+00:00 https://biolegacyresearch.com/fda-denies-beyondsprings-nda-for-neutropenia-indication/ 2021-12-02T05:01:00+00:00 https://biolegacyresearch.com/statera-gets-fda-ok-to-proceed-with-radiation-rescue-drug-development/ 2021-12-02T05:01:00+00:00 https://biolegacyresearch.com/sanofis-vaccine-pipeline-includes-10-new-candidates/ 2021-12-02T05:01:00+00:00 https://biolegacyresearch.com/supreme-court-considers-340b-drug-discount-program-while-yet-another-drugmaker-drops-out/ 2021-12-02T22:19:39+00:00 https://biolegacyresearch.com/novavax-to-create-an-omicron-specific-vaccine-while-assessing-current-jabs-effect-on-the-variant/ 2021-12-02T22:23:05+00:00 https://biolegacyresearch.com/court-rejects-modernas-challenge-to-arbutus-biopharma-patents/ 2021-12-02T22:57:09+00:00 https://biolegacyresearch.com/fda-raps-chinese-drugmaker-for-data-quality/ 2021-12-02T23:06:23+00:00 https://biolegacyresearch.com/house-passes-counting-resolution-funding-fda-through-feb-18/ 2021-12-02T23:21:40+00:00 https://biolegacyresearch.com/governments-600m-contract-with-troubled-emergent-vaccine-plant-is-no-more/ 2021-12-03T21:28:54+00:00 https://biolegacyresearch.com/chinese-api-manufacturer-draws-fda-warning-letter/ 2021-12-03T21:33:08+00:00 https://biolegacyresearch.com/dercher-enterprises-hit-with-fourth-483-in-13-years/ 2021-12-03T21:37:11+00:00 https://biolegacyresearch.com/fda-launches-nextgen-portal-for-reporting-drug-volume-data/ 2021-12-03T21:39:38+00:00 https://biolegacyresearch.com/fda-cancels-odac-meeting-on-two-drugs-with-accelerated-approvals-science-publishes-report-showing-confirmatory-trials-often-dont-happen-for-the-drugs/ 2021-12-03T22:12:00+00:00 https://biolegacyresearch.com/bayers-nubeqa-improves-overall-survival-in-metastatic-prostate-cancer/ 2021-12-03T22:13:38+00:00 https://biolegacyresearch.com/ucb-novartis-to-co-develop-two-alpha-synuclein-modulators-for-parkinsons/ 2021-12-03T22:14:34+00:00 https://biolegacyresearch.com/many-vaccines-offer-protection-as-boosters-but-pfizers-modernas-may-work-best/ 2021-12-03T22:40:12+00:00 https://biolegacyresearch.com/fda-revises-its-fiscal-2022-gdufa-science-and-research-priorities/ 2021-12-03T22:45:53+00:00 https://biolegacyresearch.com/democrats-to-meet-with-senate-parliamentarian-over-build-back-better/ 2021-12-03T23:31:38+00:00 https://biolegacyresearch.com/gilead-sciences-recalls-remdesivir-lots-over-glass-particulates/ 2021-12-07T05:01:00+00:00 https://biolegacyresearch.com/cder-publishes-manuals-on-failure-to-pay-pdufa-and-bsufa-fees/ 2021-12-07T05:01:00+00:00 https://biolegacyresearch.com/jak-inhibitors-take-a-hit-as-fda-requires-serious-box-label-warnings/ 2021-12-07T05:01:00+00:00 https://biolegacyresearch.com/aegleas-enzyme-pegzilarginase-normalizes-plasma-arginine-in-90-percent-of-patients-in-late-stage-study/ 2021-12-07T05:01:00+00:00 https://biolegacyresearch.com/biden-schumer-offer-update-on-drug-pricing-provisions-in-build-back-better-act/ 2021-12-07T05:01:00+00:00 https://biolegacyresearch.com/medicago-gets-positive-results-on-plant-based-covid-19-vaccine-using-gsk-booster/ 2021-12-07T21:43:56+00:00 https://biolegacyresearch.com/merck-halts-enrollment-in-islatravir-hiv-study/ 2021-12-07T21:52:29+00:00 https://biolegacyresearch.com/lowering-prices-for-accelerated-approval-drugs-wont-reduce-medicare-spending-study-suggests/ 2021-12-08T05:01:00+00:00 https://biolegacyresearch.com/fda-offers-advice-for-sponsors-of-individualized-gene-therapies/ 2021-12-08T05:01:00+00:00 https://biolegacyresearch.com/fda-authorizes-astrazenecas-covid-19-long-acting-antibody-combo/ 2021-12-09T05:01:00+00:00 https://biolegacyresearch.com/roche-teams-up-with-recursion-to-develop-neuroscience-cancer-drugs/ 2021-12-09T05:01:00+00:00 https://biolegacyresearch.com/two-new-studies-and-pfizer-confirm-mrna-vaccines-are-less-effective-on-omicron/ 2021-12-09T05:01:00+00:00 https://biolegacyresearch.com/allergan-settles-new-york-opioid-lawsuit-for-200-million/ 2021-12-09T05:01:00+00:00 https://biolegacyresearch.com/fda-expert-panel-shoots-down-chronic-kidney-disease-drug/ 2021-12-09T05:01:00+00:00 https://biolegacyresearch.com/fda-updates-eua-to-allow-pfizer-boosters-in-16-and-17-year-olds/ 2021-12-10T00:10:29+00:00 https://biolegacyresearch.com/fda-lifts-clinical-hold-on-apreas-eprenetapopt-nonhodgkins-lymphoma-program/ 2021-12-10T00:11:27+00:00 https://biolegacyresearch.com/cder-and-cber-issue-guidance-on-drug-trials-targeting-chronic-rhinosinusitis/ 2021-12-10T00:12:27+00:00 https://biolegacyresearch.com/fda-says-minor-cmc-changes-for-biologics-must-be-documented-in-annual-report/ 2021-12-10T00:13:31+00:00 https://biolegacyresearch.com/fda-issues-more-guidance-on-real-world-evidence-delving-into-noninterventional-studies/ 2021-12-10T00:14:50+00:00 https://biolegacyresearch.com/modernas-mrna-flu-vaccine-candidate-shows-promise-as-company-pursues-single-dose-jab-to-also-protect-against-covid-19-and-rsv/ 2021-12-13T05:01:00+00:00 https://biolegacyresearch.com/fda-adopts-ich-classifications-for-three-solvents/ 2021-12-13T05:01:00+00:00 https://biolegacyresearch.com/jj-finalizes-executive-committee-ahead-of-splitting-pharma-consumer-operations/ 2021-12-13T05:01:00+00:00 https://biolegacyresearch.com/cder-releases-draft-guidance-on-developing-pre-colonoscopy-bowel-cleansing-products/ 2021-12-13T05:01:00+00:00 https://biolegacyresearch.com/house-report-says-high-drug-prices-are-unsustainable-urges-passage-of-build-back-better/ 2021-12-13T05:01:00+00:00 https://biolegacyresearch.com/some-generics-biosimilars-cut-from-drug-pricing-provisions-in-build-back-better-bill/ 2021-12-14T05:01:00+00:00 https://biolegacyresearch.com/two-bespoke-car-t-therapies-post-positive-data/ 2021-12-14T05:01:00+00:00 https://biolegacyresearch.com/federal-court-blocks-california-law-banning-pay-for-delay-deals-by-drugmakers/ 2021-12-14T05:01:00+00:00 https://biolegacyresearch.com/fda-eases-car-t-cell-rems-during-covid-19-related-tocilizumab-shortage/ 2021-12-14T05:01:00+00:00 https://biolegacyresearch.com/pfizer-to-acquire-immuno-inflammatory-disease-focused-arena-pharmaceuticals-for-6-7-billion/ 2021-12-14T05:01:00+00:00 https://biolegacyresearch.com/pfizers-oral-at-home-covid-19-treatment-candidate-is-89-percent-effective-could-soon-grab-top-spot-from-molnupiravir/ 2021-12-14T21:21:12+00:00 https://biolegacyresearch.com/oregon-wants-to-reduce-number-of-covered-drugs-in-its-medicaid-formulary/ 2021-12-14T21:47:53+00:00 https://biolegacyresearch.com/csl-expands-into-cardio-and-renal-disease-drugs-through-11-7-billion-purchase-of-vifor-pharma/ 2021-12-14T23:03:21+00:00 https://biolegacyresearch.com/califf-sails-through-senate-confirmation-hearing/ 2021-12-14T23:10:06+00:00 https://biolegacyresearch.com/icmra-recommends-regulatory-bodies-continue-using-the-remote-inspections-begun-in-the-pandemic/ 2021-12-14T23:14:49+00:00 https://biolegacyresearch.com/fda-slaps-california-drugmaker-over-cgmp-quality-failures/ 2021-12-16T05:01:00+00:00 https://biolegacyresearch.com/sanofi-gsk-push-back-full-covid-19-booster-study-results/ 2021-12-16T05:01:00+00:00 https://biolegacyresearch.com/humana-files-suit-against-gilead-and-other-drugmakers-alleging-antitrust-schemes-to-limit-competition-for-hiv-drugs/ 2021-12-16T05:01:00+00:00 https://biolegacyresearch.com/after-delay-fda-approves-two-jak-inhibitors-for-new-indications-but-includes-significant-restrictions/ 2021-12-16T05:01:00+00:00 https://biolegacyresearch.com/fda-grants-accelerated-approval-to-first-drug-to-decrease-urine-protein-caused-by-rare-kidney-disease/ 2021-12-16T21:12:51+00:00 https://biolegacyresearch.com/astrazenecas-covid-19-vaccine-offers-no-protective-effect-against-omicron/ 2021-12-16T21:18:55+00:00 https://biolegacyresearch.com/nearly-800-drugs-are-in-development-for-rare-diseases-most-for-genetic-disorders-says-phrma/ 2021-12-16T21:52:55+00:00 https://biolegacyresearch.com/fda-prefers-automated-visual-inspection-for-particulates-in-injectables/ 2021-12-16T22:07:26+00:00 https://biolegacyresearch.com/cdc-panel-recommends-pfizer-and-moderna-vaccines-over-jjs-based-on-recent-data-on-blood-clots/ 2021-12-16T22:59:00+00:00 https://biolegacyresearch.com/first-real-world-data-suggest-omicron-illness-may-be-less-severe/ 2021-12-16T23:01:00+00:00 https://biolegacyresearch.com/fda-loosens-longstanding-restrictions-on-abortion-pill-making-it-accessible-via-mail/ 2021-12-17T00:41:34+00:00 https://biolegacyresearch.com/aduhelm-gets-thumbs-down-from-ema-as-biogen-plans-u-s-confirmatory-study/ 2021-12-20T05:01:00+00:00 https://biolegacyresearch.com/ema-panel-recommends-13-drugs-for-authorization-in-december-meeting/ 2021-12-20T05:01:00+00:00 https://biolegacyresearch.com/astrazeneca-regeneron-say-their-covid-19-antibodies-treatments-still-work-on-omicron/ 2021-12-20T05:01:00+00:00 https://biolegacyresearch.com/white-house-and-senate-democrats-to-fight-for-build-back-better-vote-in-new-year/ 2021-12-20T05:01:00+00:00 https://biolegacyresearch.com/fda-says-it-will-sic-the-ftc-on-endo-for-attempts-to-block-generic-versions-of-its-drug/ 2021-12-20T05:01:00+00:00 https://biolegacyresearch.com/federal-judge-overturns-purdue-pharmas-4-5-billion-bankruptcy-settlement-over-sackler-family-immunity-provision/ 2021-12-20T05:01:00+00:00 https://biolegacyresearch.com/fdas-fall-regulatory-agenda-adds-several-new-proposed-and-final-rules/ 2021-12-20T05:01:00+00:00 https://biolegacyresearch.com/biogen-cuts-aduhelm-cost-by-50-percent-hoping-to-secure-insurance-coverage/ 2021-12-21T05:01:00+00:00 https://biolegacyresearch.com/abbvie-presses-trade-commission-to-ban-alvotechs-humira-biosimilar-in-the-u-s/ 2021-12-21T05:01:00+00:00 https://biolegacyresearch.com/fda-puts-another-hold-on-bluebirds-sickle-cell-gene-therapy/ 2021-12-21T05:01:00+00:00 https://biolegacyresearch.com/fda-to-resume-unannounced-foreign-inspections-shortly-says-fda-official/ 2021-12-21T05:01:00+00:00 https://biolegacyresearch.com/moderna-pauses-acrimonious-bid-for-patent-on-mrna-sequence-says-more-time-is-needed-for-discussions-with-nih/ 2021-12-21T05:01:00+00:00 https://biolegacyresearch.com/novartis-gets-a-miss-and-a-hit-in-urticaria-space/ 2021-12-21T05:01:00+00:00 https://biolegacyresearch.com/many-drugs-critical-to-patient-care-are-slipping-into-shortage-due-to-prioritization-of-covid-19-products-says-report/ 2021-12-21T23:29:05+00:00 https://biolegacyresearch.com/sanofi-expands-its-cancer-drug-pipeline-through-1-billion-amunix-purchase/ 2021-12-21T23:30:09+00:00 https://biolegacyresearch.com/fda-approves-expanded-use-of-amgens-blockbuster-skin-treatment/ 2021-12-21T23:31:25+00:00 https://biolegacyresearch.com/eli-lillys-lebrikizumab-shows-positive-phase-3-results-for-atopic-dermatitis/ 2021-12-21T23:32:40+00:00 https://biolegacyresearch.com/cepi-sk-biopharma-to-develop-variant-proof-covid-19-vaccine/ 2021-12-21T23:33:55+00:00 https://biolegacyresearch.com/fda-authorizes-pfizers-covid-19-antiviral-pill/ 2021-12-22T23:28:22+00:00 https://biolegacyresearch.com/more-than-800-hospitals-pressure-hhs-to-appeal-federal-court-ruling-on-340b-drug-discount-program/ 2021-12-22T23:29:23+00:00 https://biolegacyresearch.com/fda-rejects-takedas-marketing-application-for-esophagitis-therapy/ 2021-12-22T23:30:15+00:00 https://biolegacyresearch.com/fda-places-hold-on-gileads-injectable-hiv-drug-over-possible-glass-contaminants/ 2021-12-22T23:33:46+00:00 https://biolegacyresearch.com/novartis-to-acquire-gyroscope-therapeutics-netting-a-fast-tracked-ocular-gene-therapy/ 2021-12-22T23:35:09+00:00 https://biolegacyresearch.com/short-supply-limits-access-to-newly-authorized-covid-19-oral-pills/ 2021-12-23T22:56:06+00:00 https://biolegacyresearch.com/most-covid-19-related-euas-lack-strong-supporting-evidence-jama-article-says/ 2021-12-23T22:57:38+00:00 https://biolegacyresearch.com/what-will-the-new-year-bring-for-drug-pricing-provisions-in-build-back-better/ 2021-12-23T23:18:12+00:00 https://biolegacyresearch.com/novartis-cholesterol-lowering-drug-leqvio-gains-fda-approval/ 2021-12-23T23:20:12+00:00 https://biolegacyresearch.com/vaccinated-people-infected-with-omicron-also-mount-strong-delta-resistance/ 2021-12-29T05:01:00+00:00 https://biolegacyresearch.com/cell-and-gene-therapies-saw-banner-year-with-new-indications-on-the-horizon/ 2021-12-29T05:01:00+00:00 https://biolegacyresearch.com/pennsylvania-generics-plant-rapped-for-quality-failures/ 2021-12-29T05:01:00+00:00 https://biolegacyresearch.com/fda-gives-the-ok-for-leo-pharmas-eczema-treatment/ 2021-12-29T22:17:27+00:00 https://biolegacyresearch.com/amylyxs-als-treatment-candidate-gets-priority-review/ 2021-12-29T22:19:37+00:00 https://biolegacyresearch.com/federal-court-orders-new-jersey-foundation-to-stop-distributing-misbranded-drug-for-covid-19/ 2021-12-29T22:48:13+00:00 https://biolegacyresearch.com/jjs-booster-offers-strong-protection-against-hospitalization/ 2021-12-30T22:21:08+00:00 https://biolegacyresearch.com/bridgebios-potential-cardiomyopathy-treatment-cant-cross-the-phase-3-finish-line/ 2021-12-30T22:24:05+00:00 https://biolegacyresearch.com/jury-finds-teva-liable-in-new-yorks-opioid-trial/ 2021-12-30T22:26:42+00:00 https://biolegacyresearch.com/sanofis-push-to-reinstate-lantus-patents-blocked-by-federal-court/ 2021-12-30T22:29:00+00:00 https://biolegacyresearch.com/fda-set-to-authorize-pfizer-covid-19-booster-shot-in-adolescents/ 2021-12-30T22:40:27+00:00 https://biolegacyresearch.com/pandemic-era-strategy-has-limitations-for-future-drug-development-survey-finds/ 2021-12-31T22:41:14+00:00 https://biolegacyresearch.com/without-mrna-booster-coronavac-is-useless-against-omicron/ 2021-12-31T22:42:20+00:00 https://biolegacyresearch.com/xeris-wins-fda-approval-of-recorlev-for-cushings-syndrome/ 2021-12-31T22:42:44+00:00 https://biolegacyresearch.com/fda-investigators-see-shortcomings-at-novartis-gene-therapies-facility/ 2021-12-31T22:44:26+00:00 https://biolegacyresearch.com/cms-issues-final-rule-tossing-most-favored-nation-drug-pricing-strategy/ 2022-01-05T05:01:00+00:00 https://biolegacyresearch.com/hhs-appeals-federal-court-decisions-about-controversial-340b-program/ 2022-01-05T05:01:00+00:00 https://biolegacyresearch.com/appeals-court-upholds-ruling-on-novartis-gilenya-patent/ 2022-01-05T05:01:00+00:00 https://biolegacyresearch.com/more-than-450-brand-name-drugs-have-already-seen-price-hikes-in-2022-though-most-are-modest/ 2022-01-05T05:01:00+00:00 https://biolegacyresearch.com/senate-committee-to-hold-vote-next-week-on-nominee-for-fda-commissioner/ 2022-01-05T05:01:00+00:00 https://biolegacyresearch.com/applied-therapeutics-holds-off-at-007-regulatory-push/ 2022-01-05T05:01:00+00:00 https://biolegacyresearch.com/nasal-spray-maker-amcyte-pharma-hit-with-warning-letter-over-covid-19-claims/ 2022-01-06T05:01:00+00:00 https://biolegacyresearch.com/nice-says-no-to-astrazenecas-lynparza-for-prostate-cancer/ 2022-01-06T05:01:00+00:00 https://biolegacyresearch.com/no-negotiations-happening-for-build-back-better-says-manchin/ 2022-01-06T05:01:00+00:00 https://biolegacyresearch.com/omicron-causes-delay-of-fda-inspections-as-well-as-planning-of-in-person-foreign-inspections/ 2022-01-06T05:01:00+00:00 https://biolegacyresearch.com/cders-2021-novel-drugs-report-shows-rising-trend-of-approvals/ 2022-01-06T23:14:40+00:00 https://biolegacyresearch.com/a-paltry-1-to-5-vials-per-day-of-aduhelm-are-ordered-across-thousands-of-u-s-hospitals-says-purchasing-group/ 2022-01-06T23:16:03+00:00 https://biolegacyresearch.com/fda-will-soon-decide-on-potentially-groundbreaking-bms-drug-for-advanced-melanoma/ 2022-01-06T23:17:10+00:00 https://biolegacyresearch.com/amgen-teams-with-generate-biomedicines-to-create-protein-therapeutics/ 2022-01-06T23:18:16+00:00 https://biolegacyresearch.com/fda-soon-to-consider-potentially-market-busting-immunotherapy-sintilimab-which-has-only-been-tested-in-china/ 2022-01-10T05:01:00+00:00 https://biolegacyresearch.com/icer-tirzepatide-could-be-cost-effective-in-type-2-diabetes-at-5500-to-7500-annually/ 2022-01-10T05:01:00+00:00 https://biolegacyresearch.com/sanofi-partners-with-exscientia-to-develop-15-drug-candidates/ 2022-01-10T05:01:00+00:00 https://biolegacyresearch.com/federal-judge-tells-fda-it-must-make-public-55000-pages-a-month-of-pfizer-vaccine-data/ 2022-01-10T05:01:00+00:00 https://biolegacyresearch.com/court-tosses-skinny-label-challenge-against-hikma-pharmaceuticals/ 2022-01-10T05:01:00+00:00 https://biolegacyresearch.com/novartis-options-first-in-class-antiviral-based-on-phase-2-data/ 2022-01-11T05:01:00+00:00 https://biolegacyresearch.com/seven-drugs-to-watch-in-2022-with-potential-for-blockbuster-status-by-2026-according-to-report/ 2022-01-11T05:01:00+00:00 https://biolegacyresearch.com/bayer-inks-deal-with-mammoth-bio-to-develop-gene-editing-therapies/ 2022-01-11T05:01:00+00:00 https://biolegacyresearch.com/fda-approves-idorsias-potential-blockbuster-insomnia-drug/ 2022-01-11T05:01:00+00:00 https://biolegacyresearch.com/pfizer-beam-therapeutics-to-co-develop-mrna-therapies-for-rare-diseases/ 2022-01-11T05:01:00+00:00 https://biolegacyresearch.com/industry-and-trade-groups-weigh-in-heavily-on-fdas-microbiological-contamination-draft-guidance/ 2022-01-11T22:26:00+00:00 https://biolegacyresearch.com/pfizer-hopes-for-omicron-specific-vaccine-by-march/ 2022-01-11T22:27:46+00:00 https://biolegacyresearch.com/fda-lifts-clinical-hold-on-allogenes-car-t-trials/ 2022-01-11T22:46:23+00:00 https://biolegacyresearch.com/cms-will-only-cover-aduhelm-and-other-antiamyloid-antibodies-as-part-of-clinical-trials/ 2022-01-11T23:30:00+00:00 https://biolegacyresearch.com/otc-drugmaker-in-china-draws-fda-warning-letter/ 2022-01-13T05:01:00+00:00 https://biolegacyresearch.com/cms-aduhelm-coverage-decision-frustrates-biogen-enrages-alzheimers-association/ 2022-01-13T05:01:00+00:00 https://biolegacyresearch.com/amgen-arrakis-join-forces-to-attack-disease-causing-rna/ 2022-01-13T05:01:00+00:00 https://biolegacyresearch.com/drugmakers-saw-robust-roi-and-lower-development-costs-in-2021-says-analysis/ 2022-01-13T05:01:00+00:00 https://biolegacyresearch.com/fda-warning-buprenorphine-to-treat-opioid-use-disorder-can-cause-dental-problems/ 2022-01-13T22:27:40+00:00 https://biolegacyresearch.com/sanofi-inks-deal-with-koreas-abl-bio-to-develop-candidates-for-neurodegenerative-diseases/ 2022-01-13T22:29:20+00:00 https://biolegacyresearch.com/astrazeneca-inks-deal-with-scorpion-therapeutics-to-target-undruggable-cancers/ 2022-01-13T22:48:34+00:00 https://biolegacyresearch.com/biogen-stakeholders-advocacy-group-react-to-cms-aduhelm-coverage-decision/ 2022-01-13T23:00:01+00:00 https://biolegacyresearch.com/senate-help-committee-votes-to-endorse-robert-califf-as-fda-commissioner/ 2022-01-14T05:01:00+00:00 https://biolegacyresearch.com/fda-submits-user-fee-reauthorization-commitment-letters-to-congress/ 2022-01-14T23:50:33+00:00 https://biolegacyresearch.com/cber-director-peter-marks-says-omicron-specific-shots-might-not-be-needed/ 2022-01-14T23:51:51+00:00 https://biolegacyresearch.com/gsk-and-vir-seek-fda-nod-for-intramuscular-version-of-covid-19-antibody/ 2022-01-14T23:53:08+00:00 https://biolegacyresearch.com/eu-issues-regulations-for-assigning-safety-event-evaluations-to-member-states/ 2022-01-14T23:54:27+00:00 https://biolegacyresearch.com/two-tv-ads-earn-eli-lilly-a-slap-from-fda-but-lilly-makes-good/ 2022-01-14T23:55:47+00:00 https://biolegacyresearch.com/gao-recommends-that-fda-overhaul-strategic-workforce-planning/ 2022-01-18T23:16:39+00:00 https://biolegacyresearch.com/bms-loses-appeal-over-1-2-billion-patent-verdict/ 2022-01-18T23:18:24+00:00 https://biolegacyresearch.com/clinical-holds-raise-eyebrows-about-transferrin-receptor-transport-drugs/ 2022-01-18T23:19:46+00:00 https://biolegacyresearch.com/otc-drugmaker-in-south-korea-draws-warning-letter/ 2022-01-18T23:21:21+00:00 https://biolegacyresearch.com/gilead-discovers-counterfeit-scheme-centered-on-two-of-its-hiv-drugs/ 2022-01-20T05:01:00+00:00 https://biolegacyresearch.com/teva-settles-shareholder-lawsuit-over-alleged-price-fixing-for-420-million/ 2022-01-20T05:01:00+00:00 https://biolegacyresearch.com/illinois-firm-warned-for-lax-water-system/ 2022-01-20T05:01:00+00:00 https://biolegacyresearch.com/patent-thickets-are-thwarting-u-s-availability-of-lower-cost-biosimilars-study-finds/ 2022-01-20T05:01:00+00:00 https://biolegacyresearch.com/califf-lays-out-focal-points-for-fda-if-confirmed-to-lead-it/ 2022-01-20T05:01:00+00:00 https://biolegacyresearch.com/fda-again-delays-in-person-inspections-due-to-omicron-concerns/ 2022-01-20T22:28:21+00:00 https://biolegacyresearch.com/sanofi-seeks-to-revive-antitrust-lawsuit-against-mylan-over-epipen/ 2022-01-20T22:29:48+00:00 https://biolegacyresearch.com/european-parliament-endorses-plan-to-strengthen-ema-to-better-monitor-drug-and-device-shortages/ 2022-01-20T22:34:26+00:00 https://biolegacyresearch.com/fdanews-webinar-on-challenges-facing-the-new-fda-commissioner/ 2022-01-20T22:59:58+00:00 https://biolegacyresearch.com/fdas-maintains-stable-performance-across-pdufa-and-bsufa-tasks-during-the-pandemic/ 2022-01-21T23:22:42+00:00 https://biolegacyresearch.com/pfizer-moderna-covid-19-booster-dose-effective-against-omicron-cdc-says/ 2022-01-21T23:23:54+00:00 https://biolegacyresearch.com/uks-medicines-evaluation-body-adopts-sweeping-changes/ 2022-01-21T23:25:09+00:00 https://biolegacyresearch.com/fda-lifts-clinical-hold-on-kura-oncologys-aml-drug/ 2022-01-21T23:26:28+00:00 https://biolegacyresearch.com/veklury-wins-accelerated-approval-for-treatment-of-covid-19-in-non-hospital-settings/ 2022-01-24T22:46:41+00:00 https://biolegacyresearch.com/after-winning-in-japan-gefapixant-falls-short-in-u-s/ 2022-01-24T22:49:41+00:00 https://biolegacyresearch.com/fda-issues-crl-for-pfizer-and-opko-healths-growth-hormone-treatment/ 2022-01-24T22:50:58+00:00 https://biolegacyresearch.com/gilead-pulls-zydelig-blood-cancer-indications-over-lack-of-confirmatory-trials/ 2022-01-24T23:17:46+00:00 https://biolegacyresearch.com/sanofi-teams-up-with-uk-startup-to-test-new-treatments/ 2022-01-24T23:21:00+00:00 https://biolegacyresearch.com/pfizer-urged-to-make-paxlovid-available-beyond-north-america-and-europe/ 2022-01-26T05:01:00+00:00 https://biolegacyresearch.com/fda-issues-new-guidance-on-updating-labeling-for-generics-after-revisions-to-reference-drug-labels/ 2022-01-26T05:01:00+00:00 https://biolegacyresearch.com/eli-lilly-gets-strongly-worded-untitled-letter-from-fda-about-trulicity-instagram-ad/ 2022-01-26T05:01:00+00:00 https://biolegacyresearch.com/fda-issues-draft-guidance-on-requirements-around-collecting-and-providing-samples/ 2022-01-26T05:01:00+00:00 https://biolegacyresearch.com/fda-orders-clinical-hold-on-five-trials-of-gileads-checkpoint-inhibitor-magrolimab/ 2022-01-26T22:57:05+00:00 https://biolegacyresearch.com/sponsors-still-sluggish-to-report-clinical-trial-results-analysis-finds/ 2022-01-26T22:58:21+00:00 https://biolegacyresearch.com/aurobindo-facility-in-india-draws-fda-warning-letter-india/ 2022-01-26T22:59:00+00:00 https://biolegacyresearch.com/fda-issues-final-guidance-on-submitting-andas-highlighting-recurring-deficiencies/ 2022-01-26T23:07:00+00:00 https://biolegacyresearch.com/sierra-oncology-records-success-in-late-stage-study-of-blood-cancer-drug/ 2022-01-26T23:21:14+00:00 https://biolegacyresearch.com/covid-19-woes-continue-to-plague-generic-drug-approvals/ 2022-01-26T23:30:34+00:00 https://biolegacyresearch.com/institutions-still-sluggish-to-report-clinical-trial-results-analysis-finds/ 2022-01-27T05:01:00+00:00 https://biolegacyresearch.com/generic-drug-for-chb-stayed-expensive-despite-competition-says-analysis/ 2022-01-27T21:48:44+00:00 https://biolegacyresearch.com/fda-approves-immunocores-kimmtrak-for-rare-eye-cancer/ 2022-01-27T21:49:48+00:00 https://biolegacyresearch.com/responding-to-real-world-data-guidance-industry-calls-for-flexibility-and-further-clarity/ 2022-01-27T21:51:27+00:00 https://biolegacyresearch.com/keytruda-unmasks-hiding-hiv-wins-eu-approval-for-kidney-cancer/ 2022-01-27T23:25:23+00:00 https://biolegacyresearch.com/covid-19-boosters-slash-risk-of-omicron-related-death-in-older-people/ 2022-01-27T23:27:11+00:00 https://biolegacyresearch.com/michigan-ag-seeks-to-investigate-lilly-for-grossly-excessive-insulin-prices/ 2022-01-27T23:29:00+00:00 https://biolegacyresearch.com/lilly-walks-away-from-lupus-indication-for-blockbuster-jak-inhibitor-olumiant-anticipates-crl-on-the-drugs-atopic-dermatitis-indication/ 2022-01-28T22:39:53+00:00 https://biolegacyresearch.com/itc-to-investigate-two-abbvie-competitors-for-potential-use-of-humira-trade-secrets/ 2022-01-28T22:41:44+00:00 https://biolegacyresearch.com/regeneron-and-sanofi-withdraw-sbla-for-checkpoint-inhibitor-libtayo-for-cervical-cancer/ 2022-01-28T22:42:57+00:00 https://biolegacyresearch.com/chmp-recommends-seven-new-drugs-including-two-biosimilars/ 2022-01-28T23:43:36+00:00 https://biolegacyresearch.com/eu-launches-long-awaited-clinical-trials-regulation-and-portal/ 2022-01-28T23:48:53+00:00 https://biolegacyresearch.com/deadlines-approach-for-cares-act-information-reports/ 2022-01-31T22:38:43+00:00 https://biolegacyresearch.com/fda-outlines-premarket-pathways-for-combination-products/ 2022-01-31T22:40:01+00:00 https://biolegacyresearch.com/chinese-officials-arrest-astrazeneca-employees-accused-of-insurance-fraud-executives-summoned/ 2022-01-31T22:41:13+00:00 https://biolegacyresearch.com/madrigal-unveils-positive-topline-data-for-investigational-nash-therapy/ 2022-01-31T22:43:09+00:00 https://biolegacyresearch.com/roches-vision-loss-therapy-to-compete-with-regenerons-blockbuster/ 2022-01-31T22:57:00+00:00 https://biolegacyresearch.com/covid-19-vaccine-update-pfizer-files-for-eua-in-young-children-moderna-gets-fda-nod-and-novavax-nabs-eua/ 2022-02-02T05:01:00+00:00 https://biolegacyresearch.com/nih-to-decide-whether-to-use-march-in-rights-to-cut-cost-of-prostate-cancer-drug/ 2022-02-02T05:01:00+00:00 https://biolegacyresearch.com/califf-confirmation-still-delayed-votes-not-yet-there/ 2022-02-02T05:01:00+00:00 https://biolegacyresearch.com/cder-reports-on-drug-safety-priorities-during-second-pandemic-year/ 2022-02-02T05:01:00+00:00 https://biolegacyresearch.com/fy-21-funding-levels-are-not-going-to-work-for-the-fda-in-fy-22-says-industry-watcher/ 2022-02-03T05:01:00+00:00 https://biolegacyresearch.com/three-wholesalers-and-jj-agree-to-590-million-settlement-with-native-american-tribes-over-opioid-crisis/ 2022-02-03T05:01:00+00:00 https://biolegacyresearch.com/gilead-settles-with-gsk-for-1-25-million-plus-royalties-over-viiv-patent-dispute/ 2022-02-03T05:01:00+00:00 https://biolegacyresearch.com/fda-approves-first-generic-alternative-to-restasis-for-dry-eye/ 2022-02-03T05:01:00+00:00 https://biolegacyresearch.com/upenn-sues-genentech-for-patent-infringement-over-four-breast-cancer-drugs/ 2022-02-03T05:01:00+00:00 https://biolegacyresearch.com/gilead-settles-with-gsk-for-1-25-billion-plus-royalties-over-viiv-patent-dispute/ 2022-02-03T05:01:00+00:00 https://biolegacyresearch.com/user-fee-hearing-highlights-confirmatory-studies-for-drugs-that-get-accelerated-approval/ 2022-02-04T05:01:00+00:00 https://biolegacyresearch.com/icer-says-four-covid-19-therapeutics-are-reasonably-priced-at-least-for-now/ 2022-02-04T05:01:00+00:00 https://biolegacyresearch.com/mpp-inks-deal-with-south-africas-afrigen-declaring-the-company-the-global-mrna-vaccine-technology-transfer-hub/ 2022-02-04T05:01:00+00:00 https://biolegacyresearch.com/jj-discontinues-trials-of-monoclonal-antibody-for-atopic-dermatitis/ 2022-02-04T05:01:00+00:00 https://biolegacyresearch.com/doctors-call-for-transparency-on-costs-of-federally-funded-clinical-trials/ 2022-02-04T05:01:00+00:00 https://biolegacyresearch.com/long-acting-injectable-to-prevent-hiv-not-cost-effective-study-finds/ 2022-02-04T05:01:00+00:00 https://biolegacyresearch.com/fda-issues-proposed-rule-on-standards-for-the-licensing-of-wholesale-distributors-and-3rd-party-logistics-providers/ 2022-02-07T05:01:00+00:00 https://biolegacyresearch.com/ftc-sec-target-biogen-for-aduhelm-investigations/ 2022-02-07T05:01:00+00:00 https://biolegacyresearch.com/phrma-blasts-who-efforts-to-pause-patent-rights-for-covid-19-medicines/ 2022-02-07T05:01:00+00:00 https://biolegacyresearch.com/judge-gives-thumbs-up-to-mallinckrodts-1-7-billion-opioid-settlement-and-chapter-11-exit-plan/ 2022-02-07T05:01:00+00:00 https://biolegacyresearch.com/fda-finalizes-population-pharmacokinetics-guidance/ 2022-02-07T05:01:00+00:00 https://biolegacyresearch.com/pharma-companies-press-appeals-court-not-to-revive-lawsuit-alleging-that-their-contracts-in-iraq-funded-terrorists/ 2022-02-08T05:01:00+00:00 https://biolegacyresearch.com/califf-makes-more-concessions-this-time-over-accelerated-approvals/ 2022-02-08T05:01:00+00:00 https://biolegacyresearch.com/u-s-pto-considers-crispr-patent-ownership-in-hearing/ 2022-02-08T05:01:00+00:00 https://biolegacyresearch.com/fda-cancer-lead-signals-distaste-for-sintilimabs-china-only-data-package/ 2022-02-08T05:01:00+00:00 https://biolegacyresearch.com/fda-must-hire-more-staff-for-foreign-inspections-says-gao/ 2022-02-08T05:01:00+00:00 https://biolegacyresearch.com/fda-issues-draft-guidance-for-sponsors-of-antibody-drug-conjugates/ 2022-02-09T05:01:00+00:00 https://biolegacyresearch.com/cder-issues-guidance-agenda-for-2022-features-clinical-trials-generics/ 2022-02-09T05:01:00+00:00 https://biolegacyresearch.com/covid-19s-gift-to-pfizer-record-breaking-2021-sales-stellar-2022-predictions/ 2022-02-09T05:01:00+00:00 https://biolegacyresearch.com/significant-nail-in-the-coffin-for-jacobus-lems-treatment-ruzurgi/ 2022-02-09T05:01:00+00:00 https://biolegacyresearch.com/catalents-brussels-plant-hit-for-air-purity-other-lapses/ 2022-02-09T05:01:00+00:00 https://biolegacyresearch.com/cder-guidance-agenda-for-2022-features-clinical-trials-generics/ 2022-02-09T05:01:00+00:00 https://biolegacyresearch.com/fda-says-nonopioid-analgesics-may-qualify-for-expedited-review/ 2022-02-09T23:13:32+00:00 https://biolegacyresearch.com/mediator-says-sackler-family-close-to-settlement-involving-more-money-for-opioid-victims-and-material-noneconomic-terms/ 2022-02-09T23:14:36+00:00 https://biolegacyresearch.com/senate-to-vote-on-extending-government-funding-beyond-feb-18-deadline/ 2022-02-09T23:15:49+00:00 https://biolegacyresearch.com/bristol-myers-squibbs-opdivo-posts-positive-survival-data-in-esophageal-cancer/ 2022-02-09T23:17:01+00:00 https://biolegacyresearch.com/ema-launches-center-for-real-world-data/ 2022-02-09T23:22:43+00:00 https://biolegacyresearch.com/fda-issues-warning-letter-to-drug-compounder-in-texas/ 2022-02-09T23:30:23+00:00 https://biolegacyresearch.com/iqvia-reports-record-novel-drug-launches-in-2021/ 2022-02-11T05:01:00+00:00 https://biolegacyresearch.com/fda-oncologic-drugs-committee-sends-sintilimab-back-to-the-starting-line/ 2022-02-11T05:01:00+00:00 https://biolegacyresearch.com/foundation-representing-biontech-in-conflict-with-who-efforts-to-bring-covid-19-vaccine-manufacturing-to-africa/ 2022-02-11T05:01:00+00:00 https://biolegacyresearch.com/biden-seeks-to-revive-build-back-better-targets-cutting-prescription-drug-prices/ 2022-02-11T05:01:00+00:00 https://biolegacyresearch.com/democrats-and-advocacy-groups-press-hhs-to-assert-march-in-rights-over-pricy-prostate-cancer-drug-xtandi/ 2022-02-11T05:01:00+00:00 https://biolegacyresearch.com/congressional-house-committee-escalates-cms-aduhelm-cold-war/ 2022-02-11T05:01:00+00:00 https://biolegacyresearch.com/on-procedural-grounds-fda-denies-citizen-petition-to-look-into-data-tampering-at-cassava-sciences/ 2022-02-11T23:09:29+00:00 https://biolegacyresearch.com/gene-therapy-for-rare-eye-disease-misses-in-phase-2-3-pivotal-trial/ 2022-02-11T23:10:39+00:00 https://biolegacyresearch.com/ema-safety-committee-recommends-stopping-infusions-of-hes-solutions-launches-review-of-janus-kinase-inhibitors/ 2022-02-11T23:11:42+00:00 https://biolegacyresearch.com/senate-could-vote-on-califf-nomination-and-continuing-resolution-extension-today/ 2022-02-11T23:28:32+00:00 https://biolegacyresearch.com/pfizer-biontech-delay-seeking-covid-19-vaccine-authorization-in-children-under-five/ 2022-02-11T23:45:27+00:00 https://biolegacyresearch.com/lilly-roche-genentech-storm-cms-in-support-of-antiamyloid-antibodies/ 2022-02-15T05:01:00+00:00 https://biolegacyresearch.com/why-fda-doesnt-want-to-review-sanitation-tunnels/ 2022-02-15T05:01:00+00:00 https://biolegacyresearch.com/ftc-likely-to-launch-formal-probe-into-pbms/ 2022-02-15T05:01:00+00:00 https://biolegacyresearch.com/cloture-vote-in-senate-limits-debate-on-robert-califf-full-senate-vote-on-his-confirmation-expected-today/ 2022-02-15T05:01:00+00:00 https://biolegacyresearch.com/prostate-cancer-data-shine-at-asco-conference/ 2022-02-16T05:01:00+00:00 https://biolegacyresearch.com/icer-says-payers-should-consider-eli-lillys-type-2-diabetes-drug-candidate-if-the-price-is-right/ 2022-02-16T05:01:00+00:00 https://biolegacyresearch.com/eli-lilly-and-immunogen-seal-antibody-drug-candidate-deal-with-1-7-billion-potential/ 2022-02-16T05:01:00+00:00 https://biolegacyresearch.com/robert-califf-confirmed-as-fda-commissioner-in-narrow-senate-vote/ 2022-02-16T05:01:00+00:00 https://biolegacyresearch.com/six-gop-senators-tie-vaccine-mandates-to-continuing-resolution-to-fund-government/ 2022-02-16T05:01:00+00:00 https://biolegacyresearch.com/fda-issues-warning-letter-to-indiana-chem-port/ 2022-02-16T21:04:52+00:00 https://biolegacyresearch.com/sages-novel-antidepressant-improves-symptoms-by-day-3/ 2022-02-16T21:16:56+00:00 https://biolegacyresearch.com/fda-approved-100-andas-in-2021-for-originator-drugs-with-inadequate-generic-competition/ 2022-02-16T21:54:00+00:00 https://biolegacyresearch.com/continuing-resolution-cloture-vote-slated-for-today/ 2022-02-16T22:36:00+00:00 https://biolegacyresearch.com/fda-is-firm-on-keeping-gcp-inspections-in-person/ 2022-02-16T23:06:00+00:00 https://biolegacyresearch.com/fda-approved-100th-anda-in-2021-for-originator-drugs-with-inadequate-generic-competition/ 2022-02-17T05:01:00+00:00 https://biolegacyresearch.com/astrazeneca-scores-a-legal-win-in-the-ongoing-340b-discount-drug-program-saga/ 2022-02-17T23:03:52+00:00 https://biolegacyresearch.com/pharmacokinetics-and-public-health-concerns-derail-iv-tramadol/ 2022-02-17T23:05:19+00:00 https://biolegacyresearch.com/merck-and-curve-therapeutics-team-up-to-develop-oncology-neurology-drugs/ 2022-02-17T23:06:52+00:00 https://biolegacyresearch.com/jj-inks-small-molecule-drugs-development-pact-with-remix-therapeutics/ 2022-02-17T23:09:17+00:00 https://biolegacyresearch.com/generics-maker-eci-receives-warning-letter-for-incorrectly-listing-its-products/ 2022-02-17T23:10:46+00:00 https://biolegacyresearch.com/fda-says-cares-act-information-reporting-deadlines-more-a-suggestion-than-a-requirement/ 2022-02-17T23:27:49+00:00 https://biolegacyresearch.com/senate-passes-continuing-resolution-to-avert-government-shutdown-at-midnight/ 2022-02-18T00:29:26+00:00 https://biolegacyresearch.com/amgen-terminates-trial-on-gdf-15-drug-for-obesity/ 2022-02-18T21:25:48+00:00 https://biolegacyresearch.com/patient-death-prompts-pause-in-ataras-mesothelioma-car-t-cell-study/ 2022-02-18T21:26:57+00:00 https://biolegacyresearch.com/cupid-disappoints-sanofi-regeneron-for-chronic-spontaneous-urticaria-drug/ 2022-02-18T21:36:39+00:00 https://biolegacyresearch.com/public-citizen-accuses-pfizer-of-building-paxlovid-patent-wall-pfizer-pushes-back/ 2022-02-18T22:19:28+00:00 https://biolegacyresearch.com/ftc-commissioners-deadlocked-on-investigating-pbms-which-kills-investigation/ 2022-02-18T22:25:36+00:00 https://biolegacyresearch.com/fda-commissioner-califf-tweets-about-his-priorities/ 2022-02-18T23:24:08+00:00 https://biolegacyresearch.com/moderna-to-develop-three-new-mrna-vaccines/ 2022-02-18T23:25:45+00:00 https://biolegacyresearch.com/more-liver-cancer-worries-stall-pku-gene-therapy-study/ 2022-02-22T23:21:31+00:00 https://biolegacyresearch.com/four-lots-of-astrazenecas-covid-19-vaccine-unearthed-at-emergents-troubled-baltimore-manufacturing-plant/ 2022-02-22T23:23:05+00:00 https://biolegacyresearch.com/fda-issues-warning-letter-to-cytodyn-about-covid-19-claims-in-video-interview/ 2022-02-22T23:25:54+00:00 https://biolegacyresearch.com/european-medicines-network-adopts-common-standard-for-electronic-product-information/ 2022-02-22T23:33:09+00:00 https://biolegacyresearch.com/ema-recommended-53-medicines-with-a-new-active-substance-in-2021-up-35-percent-over-2020/ 2022-02-24T05:01:00+00:00 https://biolegacyresearch.com/regeneron-api-facility-draws-form-483-for-lax-recordkeeping-sanitation/ 2022-02-24T05:01:00+00:00 https://biolegacyresearch.com/takeda-and-code-bio-form-partnership-to-develop-gene-therapies/ 2022-02-24T05:01:00+00:00 https://biolegacyresearch.com/two-companies-hit-with-fda-warning-letters-for-selling-unapproved-and-misbranded-drugs-for-covid-19/ 2022-02-24T05:01:00+00:00 https://biolegacyresearch.com/fdas-pre-approval-inspections-fell-by-more-than-50-percent-in-2021-report-says/ 2022-02-24T05:01:00+00:00 https://biolegacyresearch.com/sanofi-gsk-seek-vaccine-authorization-as-both-primary-series-and-booster/ 2022-02-24T05:01:00+00:00 https://biolegacyresearch.com/fdanews-webinar-highlights-drawbacks-to-remote-inspections/ 2022-02-24T22:58:23+00:00 https://biolegacyresearch.com/for-kodiaks-macular-degeneration-antibody-just-as-good-isnt-good-enough/ 2022-02-24T22:59:29+00:00 https://biolegacyresearch.com/astrazeneca-and-daiichi-sankyo-report-encouraging-results-from-enhertu-trial/ 2022-02-24T23:03:27+00:00 https://biolegacyresearch.com/burst-biologics-warned-for-failing-to-guard-its-blood-products-against-contamination/ 2022-02-24T23:22:02+00:00 https://biolegacyresearch.com/fda-issues-third-complete-response-letter-for-mallinckrodts-terlipressin/ 2022-02-24T23:33:35+00:00 https://biolegacyresearch.com/jj-and-three-large-wholesalers-reach-opioid-settlement-deal-of-26b/ 2022-02-25T23:11:35+00:00 https://biolegacyresearch.com/fda-finalizes-guidance-on-patient-focused-drug-development/ 2022-02-25T23:12:43+00:00 https://biolegacyresearch.com/fda-expands-jardiance-approvals-to-include-heart-failure-patients-with-preserved-ejection-fraction/ 2022-02-25T23:14:35+00:00 https://biolegacyresearch.com/mumbai-based-macleods-pharmaceuticals-receives-483-noting-unclean-equipment/ 2022-02-25T23:15:41+00:00 https://biolegacyresearch.com/chmp-endorses-13-new-drugs-during-monthly-meeting/ 2022-02-25T23:16:59+00:00 https://biolegacyresearch.com/amryt-draws-crl-for-rare-skin-disease-therapy/ 2022-03-01T05:01:00+00:00 https://biolegacyresearch.com/viatris-agrees-to-settle-epipen-antitrust-litigation-for-264m/ 2022-03-01T05:01:00+00:00 https://biolegacyresearch.com/fda-denies-reatas-new-drug-application-for-bardoxolone/ 2022-03-01T05:01:00+00:00 https://biolegacyresearch.com/dupixent-improves-symptoms-and-reduces-inflammatory-cells-in-esophageal-disorder/ 2022-03-01T05:01:00+00:00 https://biolegacyresearch.com/viatris-selling-its-biosimilars-business-to-bangalore-based-biocon-for-up-to-3-3b/ 2022-03-01T05:01:00+00:00 https://biolegacyresearch.com/cell-gene-therapy-fueled-large-surge-in-clinical-holds-last-year/ 2022-03-01T05:01:00+00:00 https://biolegacyresearch.com/gilead-sciences-draws-complete-response-letter-for-lenacapavir/ 2022-03-02T05:01:00+00:00 https://biolegacyresearch.com/fdas-final-guidance-on-pre-launch-drug-importation-largely-tracks-draft-policy/ 2022-03-02T05:01:00+00:00 https://biolegacyresearch.com/abbvie-expands-its-neuroscience-portfolio-with-purchase-of-syndesi-therapeutics/ 2022-03-02T05:01:00+00:00 https://biolegacyresearch.com/pfizer-touts-secondary-endpoints-in-failed-c-difficile-vaccine-study/ 2022-03-02T05:01:00+00:00 https://biolegacyresearch.com/patent-board-issues-crispr-technology-patents-to-harvard-and-mits-broad-institute/ 2022-03-02T05:01:00+00:00 https://biolegacyresearch.com/legend-janssen-pick-up-fda-approval-for-co-developed-car-t-treatment/ 2022-03-02T05:01:00+00:00 https://biolegacyresearch.com/sanofi-taps-adagene-in-antibody-development-deal-potentially-worth-more-than-2-5b/ 2022-03-03T00:00:15+00:00 https://biolegacyresearch.com/business-leaders-agree-to-reject-russian-investment-cooperation/ 2022-03-03T00:00:57+00:00 https://biolegacyresearch.com/osel-reports-promising-results-from-immunotherapy-study-as-finch-trial-stalls/ 2022-03-03T00:01:40+00:00 https://biolegacyresearch.com/herbal-tea-company-gets-fda-warning-letter-for-drug-claims/ 2022-03-03T00:02:00+00:00 https://biolegacyresearch.com/fda-commits-to-accelerating-and-improving-cancer-research-issuing-trio-of-final-guidances/ 2022-03-03T00:02:27+00:00 https://biolegacyresearch.com/sanofi-reports-a-sixth-year-of-declining-prices-as-lawmakers-cite-increases/ 2022-03-03T00:18:49+00:00 https://biolegacyresearch.com/biden-continued-to-promote-languishing-build-back-better-bills-drug-pricing-fixes-during-state-of-the-union-address/ 2022-03-03T00:34:54+00:00 https://biolegacyresearch.com/purdue-pharma-sackler-family-reach-6-billion-settlement-with-holdout-states/ 2022-03-03T22:48:00+00:00 https://biolegacyresearch.com/fda-starts-releasing-thousands-of-pfizer-covid-19-vaccine-documents/ 2022-03-03T22:50:00+00:00 https://biolegacyresearch.com/fda-presses-industry-to-be-recall-ready-in-final-guidance-on-voluntary-recalls/ 2022-03-03T22:51:01+00:00 https://biolegacyresearch.com/roches-skyline-study-will-test-gantenerumab-in-presymptomatic-patients/ 2022-03-03T22:52:12+00:00 https://biolegacyresearch.com/astrazeneca-and-sanofis-rsv-vaccine-candidate-met-primary-endpoint-in-phase-3-trial-of-general-population-infants/ 2022-03-03T22:53:20+00:00 https://biolegacyresearch.com/civica-and-partners-plan-on-providing-affordable-insulin-drugs/ 2022-03-03T23:16:41+00:00 https://biolegacyresearch.com/washington-state-could-become-6th-state-to-create-a-drug-affordability-board/ 2022-03-07T05:01:00+00:00 https://biolegacyresearch.com/drug-recalls-were-down-in-2021-but-appear-back-on-the-rise-as-pandemic-slows-says-report/ 2022-03-07T05:01:00+00:00 https://biolegacyresearch.com/eli-lillys-arthritis-drug-shows-efficacy-for-covid-19-patients/ 2022-03-07T05:01:00+00:00 https://biolegacyresearch.com/sec-subpoenas-fibrogen-over-falsified-heart-safety-data-for-anemia-drug/ 2022-03-07T05:01:00+00:00 https://biolegacyresearch.com/nasem-calls-for-multiple-supply-chain-measures-for-future-shortages/ 2022-03-08T05:01:00+00:00 https://biolegacyresearch.com/gileads-trodelvy-scores-in-phase-3-but-just-how-much-isnt-clear/ 2022-03-08T05:01:00+00:00 https://biolegacyresearch.com/opdivo-gains-fda-approval-for-nonsmall-cell-lung-cancer/ 2022-03-08T05:01:00+00:00 https://biolegacyresearch.com/novavax-resolves-manufacturing-problems-tied-to-covid-19-vaccine-eua/ 2022-03-08T05:01:00+00:00 https://biolegacyresearch.com/teva-natco-announce-first-u-s-generics-of-bristol-myers-squibbs-cancer-drug-revlimid/ 2022-03-09T05:01:00+00:00 https://biolegacyresearch.com/novartis-picks-up-three-gene-therapy-viral-vectors-from-voyager/ 2022-03-09T05:01:00+00:00 https://biolegacyresearch.com/icmra-starting-pilot-projects-on-hybrid-inspections-collaborative-assessments/ 2022-03-09T05:01:00+00:00 https://biolegacyresearch.com/proposed-legislation-would-make-it-easier-to-dump-ineffective-accelerated-approval-drugs/ 2022-03-09T05:01:00+00:00 https://biolegacyresearch.com/analysis-fdas-five-year-diversity-strategy-fell-short-for-black-patients/ 2022-03-09T21:33:45+00:00 https://biolegacyresearch.com/sanofis-sobis-hemophilia-a-treatment-shows-efficacy-in-phase-3-trial/ 2022-03-09T21:35:02+00:00 https://biolegacyresearch.com/catalent-facility-cited-for-equipment-validation-lapses/ 2022-03-09T21:36:14+00:00 https://biolegacyresearch.com/fda-updates-supply-chain-guidance-on-verifying-suspect-products/ 2022-03-09T22:43:32+00:00 https://biolegacyresearch.com/lawmakers-poised-to-vote-on-cr-and-omnibus-bill/ 2022-03-09T23:18:49+00:00 https://biolegacyresearch.com/house-lawmakers-approve-1-5-trillion-funding-bill-for-fiscal-2022/ 2022-03-10T05:01:00+00:00 https://biolegacyresearch.com/novartis-will-manufacture-carismas-investigational-car-m-cancer-treatment/ 2022-03-10T22:26:49+00:00 https://biolegacyresearch.com/janssens-puerto-rico-plant-receives-form-483-for-multiple-quality-unit-lapses/ 2022-03-10T22:29:39+00:00 https://biolegacyresearch.com/combination-product-manufacturers-must-be-bilingual-when-it-comes-to-regulations/ 2022-03-10T22:32:10+00:00 https://biolegacyresearch.com/senate-poised-to-pass-1-5-trillion-omnibus-bill-to-fund-government-for-fy22/ 2022-03-10T23:00:00+00:00 https://biolegacyresearch.com/venatorxs-combination-antibiotic-will-head-to-fda/ 2022-03-11T22:37:58+00:00 https://biolegacyresearch.com/abbvie-wants-to-expand-quliptas-indications-to-include-chronic-migraine-prevention/ 2022-03-11T22:41:45+00:00 https://biolegacyresearch.com/the-public-health-emergency-may-not-officially-end-for-a-long-time-say-epidemiologists/ 2022-03-11T22:46:29+00:00 https://biolegacyresearch.com/gingi-pak-draws-form-483-for-failing-to-conduct-microbiological-testing/ 2022-03-11T22:50:28+00:00 https://biolegacyresearch.com/puerto-rico-otc-facility-cited-for-lab-operations-cleanliness-observations/ 2022-03-14T21:35:00+00:00 https://biolegacyresearch.com/nektars-immunotherapy-paired-with-bms-blockbuster-opdivo-missed-key-endpoints-in-melanoma-trial/ 2022-03-14T21:41:33+00:00 https://biolegacyresearch.com/congress-sends-letter-to-treasury-doj-on-opioid-related-tax-benefit-claims/ 2022-03-14T21:45:00+00:00 https://biolegacyresearch.com/astrazeneca-gets-complete-response-letter-over-chronic-rhinosinusitis-drug/ 2022-03-14T21:48:00+00:00 https://biolegacyresearch.com/fda-increases-otc-monograph-user-fees-by-19-percent-for-fiscal-2022/ 2022-03-14T22:36:19+00:00 https://biolegacyresearch.com/ema-seeks-comments-on-its-draft-guideline-on-drug-risks-in-pregnancy/ 2022-03-14T22:47:00+00:00 https://biolegacyresearch.com/fda-published-draft-guidance-on-development-of-car-t-cell-products/ 2022-03-16T04:01:00+00:00 https://biolegacyresearch.com/fda-offers-guidance-on-human-gene-therapy-products-incorporating-human-genome-editing/ 2022-03-16T04:01:00+00:00 https://biolegacyresearch.com/fda-cites-new-jersey-plant-for-quality-deficiencies/ 2022-03-16T04:01:00+00:00 https://biolegacyresearch.com/competitors-team-up-to-develop-alzheimers-digital-clinical-measures/ 2022-03-16T04:01:00+00:00 https://biolegacyresearch.com/merck-drops-late-stage-trial-of-keytruda-and-lynparza-for-advanced-prostate-cancer/ 2022-03-16T04:01:00+00:00 https://biolegacyresearch.com/biogens-new-data-show-cognitive-benefits-associated-with-tau-changes/ 2022-03-16T21:53:00+00:00 https://biolegacyresearch.com/fda-expediting-pfizers-biontechs-eua-request-for-a-second-covid-19-booster/ 2022-03-16T21:55:10+00:00 https://biolegacyresearch.com/fda-approves-first-generic-of-astrazenecas-symbicort/ 2022-03-16T21:56:49+00:00 https://biolegacyresearch.com/fda-issues-warning-letter-for-website-making-unapproved-hydroxychloroquine-claims/ 2022-03-16T21:58:10+00:00 https://biolegacyresearch.com/senate-finance-committee-examines-high-prescription-drug-prices-as-lawmakers-respond-to-phrma/ 2022-03-16T22:43:02+00:00 https://biolegacyresearch.com/astrazeneca-reaches-775-million-settlement-resolving-ultomiris-patent-dispute/ 2022-03-18T04:01:00+00:00 https://biolegacyresearch.com/gilead-becomes-15th-major-drugmaker-to-limit-its-participation-in-the-340b-drug-discount-program/ 2022-03-18T04:01:00+00:00 https://biolegacyresearch.com/new-alzheimers-prevention-trial-combines-anti-tau-and-antiamyloid-antibodies/ 2022-03-18T04:01:00+00:00 https://biolegacyresearch.com/alnylam-pharmaceuticals-sues-pfizer-and-moderna-over-lnp-technology-moderna-pushes-back/ 2022-03-18T04:01:00+00:00 https://biolegacyresearch.com/new-jersey-compounding-pharmacy-cited-for-lax-quality-sterility/ 2022-03-18T04:01:00+00:00 https://biolegacyresearch.com/iotech-international-receives-warning-letter-for-misbranded-drugs/ 2022-03-21T04:01:00+00:00 https://biolegacyresearch.com/mercks-keytruda-posts-favorable-results-in-phase-3-study-of-early-stage-nsclc/ 2022-03-21T04:01:00+00:00 https://biolegacyresearch.com/ema-panel-calls-for-safety-updates-for-jjs-modernas-covid-19-vaccines/ 2022-03-21T04:01:00+00:00 https://biolegacyresearch.com/biggest-decreases-in-tau-predict-best-response-to-aduhelm/ 2022-03-21T04:01:00+00:00 https://biolegacyresearch.com/democrats-push-biden-to-issue-executive-orders-on-drug-pricing-covid-19-ip/ 2022-03-21T04:01:00+00:00 https://biolegacyresearch.com/moderna-and-pfizer-push-for-euas-for-fourth-booster-study-questions-its-effectiveness/ 2022-03-21T04:01:00+00:00 https://biolegacyresearch.com/phrma-supports-diversity-in-trials-balks-at-mandates/ 2022-03-21T04:01:00+00:00 https://biolegacyresearch.com/bms-sues-astrazeneca-claiming-checkpoint-inhibitor-patent-infringement/ 2022-03-21T21:27:18+00:00 https://biolegacyresearch.com/protalix-and-chiesi-report-positive-results-from-fabry-disease-trial/ 2022-03-21T21:28:00+00:00 https://biolegacyresearch.com/uspto-to-decide-on-patent-extension-for-aav-tech-used-in-novartis-zolgensma/ 2022-03-21T22:04:00+00:00 https://biolegacyresearch.com/baxter-gets-form-483-for-observations-of-recurring-vermin-lack-of-protocols-and-access/ 2022-03-21T22:23:32+00:00 https://biolegacyresearch.com/volastra-teams-up-with-bms-to-develop-targeted-cancer-drugs/ 2022-03-21T22:43:28+00:00 https://biolegacyresearch.com/at-public-meeting-biosimilars-industry-lets-fda-know-whats-still-lacking-in-its-communications/ 2022-03-23T04:01:00+00:00 https://biolegacyresearch.com/jj-is-latest-big-drugmaker-to-limit-participation-in-the-340b-drug-discount-program/ 2022-03-23T04:01:00+00:00 https://biolegacyresearch.com/fda-declares-some-ophthalmic-products-combo-instead-of-just-drug-products/ 2022-03-23T04:01:00+00:00 https://biolegacyresearch.com/belcher-pharmaceuticals-receives-form-483-for-lab-and-production-quality-issues/ 2022-03-23T04:01:00+00:00 https://biolegacyresearch.com/pfizers-etrasimod-shows-promise-for-treatment-of-ulcerative-colitis/ 2022-03-24T04:01:00+00:00 https://biolegacyresearch.com/moderna-touts-development-of-two-new-respiratory-focused-mrna-vaccines/ 2022-03-24T04:01:00+00:00 https://biolegacyresearch.com/us-pharmacopeias-new-medicine-supply-map-shows-most-apis-made-in-india/ 2022-03-24T04:01:00+00:00 https://biolegacyresearch.com/argenxs-phase-3-data-shows-promise-for-subcutaneous-treatment-of-generalized-myasthenia-gravis/ 2022-03-24T04:01:00+00:00 https://biolegacyresearch.com/florida-drug-company-says-fda-warning-letter-was-due-to-clerical-error/ 2022-03-24T04:01:00+00:00 https://biolegacyresearch.com/eli-lillys-investigational-checkpoint-inhibitor-for-nsclc-rejected-over-china-only-study/ 2022-03-25T04:01:00+00:00 https://biolegacyresearch.com/premier-trends-draws-fda-warning-letter-for-making-drug-claims/ 2022-03-25T04:01:00+00:00 https://biolegacyresearch.com/astrazenecas-checkpoint-inhibitor-imfinzi-flops-in-cervical-cancer-trial/ 2022-03-25T04:01:00+00:00 https://biolegacyresearch.com/minnesota-facility-cited-for-quality-lapses-some-repeated/ 2022-03-25T04:01:00+00:00 https://biolegacyresearch.com/emas-chmp-recommends-five-new-drugs-during-monthly-meeting/ 2022-03-28T04:01:00+00:00 https://biolegacyresearch.com/merck-gets-fosamax-bone-fracture-risk-lawsuits-tossed-out-again/ 2022-03-28T04:01:00+00:00 https://biolegacyresearch.com/novo-nordisk-novartis-settle-patent-dispute-over-diabetes-blockbuster-victoza/ 2022-03-28T04:01:00+00:00 https://biolegacyresearch.com/fda-denies-approval-of-takedas-natpara-in-complete-response-letter/ 2022-03-28T04:01:00+00:00 https://biolegacyresearch.com/the-night-before-trial-sun-pharmaceuticals-owners-of-ranbaxy-settles-multiple-suits-for-485m/ 2022-03-28T04:01:00+00:00 https://biolegacyresearch.com/coalition-calls-for-lower-drug-prices-using-federal-march-in-rights/ 2022-03-28T04:01:00+00:00 https://biolegacyresearch.com/fda-amends-gsks-virs-sotrovimab-eua-after-studies-show-the-antibody-isnt-effective-against-new-omicron-variant/ 2022-03-28T21:58:49+00:00 https://biolegacyresearch.com/fda-tells-mei-and-kyowa-kirin-to-conduct-phase-3-trial-before-it-will-consider-accelerated-approval-for-lymphoma-drug/ 2022-03-28T21:59:58+00:00 https://biolegacyresearch.com/u-s-cancer-drug-prices-continue-to-rise-despite-competition/ 2022-03-28T22:01:31+00:00 https://biolegacyresearch.com/three-interleukin-inhibitors-grab-headlines-at-aad-meeting/ 2022-03-28T22:03:04+00:00 https://biolegacyresearch.com/president-biden-proposes-significant-increase-in-fdas-fiscal-2023-funding/ 2022-03-28T23:05:32+00:00 https://biolegacyresearch.com/amylyx-wages-battle-for-its-als-candidate-today/ 2022-03-29T22:08:00+00:00 https://biolegacyresearch.com/fda-authorizes-second-covid-19-booster-shots-for-older-adults-immunocompromised-patients/ 2022-03-29T22:09:46+00:00 https://biolegacyresearch.com/sanofi-and-igm-biosciences-ink-collaboration-agreement-potentially-worth-6-billion/ 2022-03-29T22:10:58+00:00 https://biolegacyresearch.com/diabetes-drug-metformin-linked-to-40-percent-higher-birth-defect-risk-study-shows/ 2022-03-29T22:12:13+00:00 https://biolegacyresearch.com/fda-sends-warning-letters-to-two-companies-claiming-covid-19-treatments/ 2022-03-29T22:36:07+00:00 https://biolegacyresearch.com/polish-otc-manufacturer-receives-warning-letter-for-homeopathic-cream-thats-100m-times-too-strong/ 2022-03-31T04:01:00+00:00 https://biolegacyresearch.com/factoring-in-inflation-wholesale-and-net-prices-of-brand-name-drugs-dropped-in-late-2021-report-says/ 2022-03-31T04:01:00+00:00 https://biolegacyresearch.com/roches-investigational-drug-tiragolumab-fails-in-phase-3-lung-cancer-study/ 2022-03-31T04:01:00+00:00 https://biolegacyresearch.com/biogen-submits-four-year-phase-4-study-protocol-for-fda-approval/ 2022-03-31T04:01:00+00:00 https://biolegacyresearch.com/fda-officials-look-to-set-the-record-straight-on-definition-of-digital-biomarker/ 2022-03-31T04:01:00+00:00 https://biolegacyresearch.com/fda-advisory-panel-votes-down-amylyx-pharmaceuticals-als-drug-candidate/ 2022-03-31T04:01:00+00:00 https://biolegacyresearch.com/house-passes-bill-to-cap-insulin-prices/ 2022-04-01T04:01:00+00:00 https://biolegacyresearch.com/abbvie-teva-settle-opioid-cases-with-florida-for-almost-330-million/ 2022-04-01T04:01:00+00:00 https://biolegacyresearch.com/fda-details-covid-19-booster-dose-immunogenicity-studies-in-final-guidance/ 2022-04-01T04:01:00+00:00 https://biolegacyresearch.com/clovis-rubraca-will-advance-on-positive-phase-3-topline-numbers/ 2022-04-01T04:01:00+00:00 https://biolegacyresearch.com/akebias-vadadustat-receives-fda-complete-response-letter/ 2022-04-01T04:01:00+00:00 https://biolegacyresearch.com/doj-begins-investigation-into-widespread-counterfeit-hiv-meds-trafficking-scheme/ 2022-04-01T04:01:00+00:00 https://biolegacyresearch.com/fda-hits-cytodyn-with-partial-clinical-hold-in-hiv-and-full-clinical-hold-in-covid-19/ 2022-04-01T22:21:59+00:00 https://biolegacyresearch.com/fresenius-kabi-expands-into-biosimilars-with-547m-stake-in-mabxience/ 2022-04-01T22:22:39+00:00 https://biolegacyresearch.com/cerevance-plans-pivotal-study-of-novel-parkinsons-drug/ 2022-04-01T22:23:22+00:00 https://biolegacyresearch.com/janssens-xarelto-posts-positive-phase-3-results-in-pad-following-ler/ 2022-04-01T22:24:11+00:00 https://biolegacyresearch.com/ich-releases-draft-guidelines-on-analytical-testing-methods-development/ 2022-04-01T22:25:08+00:00 https://biolegacyresearch.com/fda-greenlights-yescarta-for-relapsed-refractory-large-b-cell-lymphoma/ 2022-04-04T20:05:00+00:00 https://biolegacyresearch.com/west-virginias-opioid-trial-against-jj-teva-and-abbvie-begins/ 2022-04-04T21:23:00+00:00 https://biolegacyresearch.com/fda-restricts-sotrovimab-use-in-more-states-over-ba-2-subvariant-efficacy-concerns/ 2022-04-04T21:24:00+00:00 https://biolegacyresearch.com/bms-heart-failure-drug-mavacamten-posts-positive-data-at-acc/ 2022-04-04T21:25:00+00:00 https://biolegacyresearch.com/roches-ocrevus-demonstrates-hints-of-disease-modification-cognitive-boost/ 2022-04-04T21:26:00+00:00 https://biolegacyresearch.com/fdas-vaccines-committee-wrestles-with-the-future-of-covid-19-vaccination/ 2022-04-05T21:34:44+00:00 https://biolegacyresearch.com/bayers-kerendia-confers-some-cardio-and-kidney-protective-effects-in-subanalysis/ 2022-04-05T21:35:45+00:00 https://biolegacyresearch.com/hhs-office-of-inspector-general-calls-for-more-biosimilar-coverage-in-medicare-part-d/ 2022-04-05T21:54:21+00:00 https://biolegacyresearch.com/commissioner-califf-calls-for-better-use-of-health-data/ 2022-04-05T22:42:49+00:00 https://biolegacyresearch.com/fda-rescinds-emergency-authorization-of-glaxosmithklines-and-vir-biotechnologys-covid-19-treatment/ 2022-04-05T22:50:36+00:00 https://biolegacyresearch.com/peter-marks-envisions-new-development-model-for-gene-therapies/ 2022-04-06T20:21:26+00:00 https://biolegacyresearch.com/citius-will-advance-oncology-drug-based-on-diphtheria-toxin/ 2022-04-06T21:29:03+00:00 https://biolegacyresearch.com/lundbeck-reports-favorable-results-in-chronic-migraine-study-for-vyepti/ 2022-04-06T21:30:43+00:00 https://biolegacyresearch.com/fda-releases-final-guidance-on-chronic-hepatitis-b-drug-development/ 2022-04-06T22:05:50+00:00 https://biolegacyresearch.com/agencies-invite-comments-on-ich-draft-guidelines-on-pediatric-extrapolation-compound-specific-acceptable-intakes/ 2022-04-06T22:07:06+00:00 https://biolegacyresearch.com/vaccines-committee-doesnt-like-the-sound-of-repeat-covid-19-boosters/ 2022-04-06T22:38:25+00:00 https://biolegacyresearch.com/cder-director-patrizia-cavazzoni-discusses-priorities-for-fiscal-2023/ 2022-04-06T22:41:13+00:00 https://biolegacyresearch.com/pfizer-acquires-rsv-drug-candidates-through-purchase-of-reviral/ 2022-04-07T21:47:18+00:00 https://biolegacyresearch.com/nice-does-about-face-on-cost-adjusted-bavencio-but-rejects-pricey-troveldy/ 2022-04-07T21:49:57+00:00 https://biolegacyresearch.com/biosimilars-generics-to-slow-overall-pace-of-growth-in-u-s-drug-spending-this-year/ 2022-04-07T22:54:20+00:00 https://biolegacyresearch.com/cms-denies-broad-aduhelm-payments-but-expands-paths-to-coverage/ 2022-04-07T23:45:45+00:00 https://biolegacyresearch.com/fda-moves-ahead-with-program-allowing-drug-imports-from-canada/ 2022-04-07T23:47:27+00:00 https://biolegacyresearch.com/sensory-cloud-warned-for-unapproved-drug-making-covid-19-claims/ 2022-04-08T21:34:00+00:00 https://biolegacyresearch.com/outsourcing-in-trials-expected-to-rise-in-cost-and-use-this-year/ 2022-04-08T22:02:46+00:00 https://biolegacyresearch.com/fda-adopts-ich-guidelines-on-quality-in-clinical-trials/ 2022-04-08T22:04:27+00:00 https://biolegacyresearch.com/fda-proposes-quality-rating-system-for-manufacturers/ 2022-04-08T22:49:37+00:00 https://biolegacyresearch.com/fda-and-cms-clarify-their-roles-in-wake-of-aduhelm-decision-on-medicare-access/ 2022-04-08T23:40:24+00:00 https://biolegacyresearch.com/lawmakers-introduce-flurry-of-bills-on-drug-pricing-and-supply-issues/ 2022-04-08T23:41:34+00:00 https://biolegacyresearch.com/aduhelms-coverage-decision-leaves-a-path-for-other-investigational-antiamyloid-antibodies/ 2022-04-11T22:07:00+00:00 https://biolegacyresearch.com/claims-for-unapproved-nasal-spray-draw-fda-warning-letter/ 2022-04-11T22:11:28+00:00 https://biolegacyresearch.com/cber-report-shows-slight-dip-in-regenerative-medicine-designation-requests/ 2022-04-11T22:26:00+00:00 https://biolegacyresearch.com/ema-offers-guidance-on-handling-confidential-information-when-posting-trial-documents/ 2022-04-11T22:27:31+00:00 https://biolegacyresearch.com/prac-finds-no-link-between-autoimmune-hepatitis-and-mrna-based-covid-19-vaccines/ 2022-04-11T22:31:53+00:00 https://biolegacyresearch.com/vanda-sues-fda-to-force-disclosure-of-crl-documents/ 2022-04-12T22:21:55+00:00 https://biolegacyresearch.com/fda-releases-final-guidance-on-submitting-promotional-materials-both-electronically-and-otherwise/ 2022-04-12T22:23:55+00:00 https://biolegacyresearch.com/clinical-hold-news-from-two-companies-hiccup-on-the-way-to-an-snda-for-another/ 2022-04-12T22:25:12+00:00 https://biolegacyresearch.com/verus-stops-covid-19-treatment-trial-in-face-of-overwhelmingly-positive-results/ 2022-04-12T22:29:27+00:00 https://biolegacyresearch.com/bausch-health-gets-fda-reprimand-for-misleading-video-and-webpage/ 2022-04-12T22:47:09+00:00 https://biolegacyresearch.com/bluebird-bios-2-million-gene-therapy-is-worth-the-cost-icer-says/ 2022-04-13T21:29:15+00:00 https://biolegacyresearch.com/fda-sends-warning-letters-to-three-drug-manufacturers/ 2022-04-13T21:46:36+00:00 https://biolegacyresearch.com/two-websites-selling-adderall-receive-fda-warning-letters/ 2022-04-13T21:51:25+00:00 https://biolegacyresearch.com/gsk-picks-up-sierra-oncology-and-investigational-cancer-drug/ 2022-04-13T22:01:18+00:00 https://biolegacyresearch.com/fda-issues-manual-on-complex-apis/ 2022-04-13T22:37:14+00:00 https://biolegacyresearch.com/fda-recommends-sponsors-submit-plans-for-achieving-trial-diversity/ 2022-04-13T22:38:44+00:00 https://biolegacyresearch.com/fda-extends-bla-review-for-regenerons-covid-19-antibody-cocktail/ 2022-04-14T21:47:04+00:00 https://biolegacyresearch.com/renewal-of-public-health-emergency-means-fdas-pandemic-guidance-still-applies/ 2022-04-14T22:08:07+00:00 https://biolegacyresearch.com/congress-urges-drugmakers-to-supply-over-the-counter-naloxone/ 2022-04-14T22:36:48+00:00 https://biolegacyresearch.com/fda-to-rescind-breakthrough-therapy-designation-for-protagonists-blood-cancer-drug/ 2022-04-14T22:38:23+00:00 https://biolegacyresearch.com/fda-issues-final-guidance-on-bioavailability-studies-for-oral-drugs/ 2022-04-14T22:40:09+00:00 https://biolegacyresearch.com/ftc-extends-public-comment-period-for-request-for-information-on-impact-of-pharmacy-benefit-managers/ 2022-04-14T23:11:01+00:00 https://biolegacyresearch.com/cder-offers-guidance-on-developing-drugs-for-celiac-disease/ 2022-04-18T20:51:00+00:00 https://biolegacyresearch.com/fdas-office-of-generic-drugs-issues-revised-mapp-in-ba-and-be-studies/ 2022-04-18T21:08:00+00:00 https://biolegacyresearch.com/data-extrapolations-often-define-prescribing-indications-study-finds/ 2022-04-18T21:31:11+00:00 https://biolegacyresearch.com/jj-settles-west-virginia-opioid-suit-for-99-million/ 2022-04-18T21:37:01+00:00 https://biolegacyresearch.com/noven-pharmaceuticals-dinged-by-fda-for-lax-cleaning-verification/ 2022-04-18T22:11:33+00:00 https://biolegacyresearch.com/indian-generics-maker-hit-with-483-over-operations-at-api-facility/ 2022-04-19T21:47:03+00:00 https://biolegacyresearch.com/plastikon-hit-with-form-483-over-lax-testing-and-documentation/ 2022-04-19T21:48:05+00:00 https://biolegacyresearch.com/cancer-hospitals-mark-up-drugs-by-as-much-as-633-percent/ 2022-04-19T21:59:45+00:00 https://biolegacyresearch.com/pfizers-oral-covid-19-treatment-scores-in-phase-2-3/ 2022-04-19T22:13:21+00:00 https://biolegacyresearch.com/fda-advisory-panel-meets-today-to-discuss-demonstrated-substantial-toxicity-of-pi3k-inhibitors/ 2022-04-21T04:01:00+00:00 https://biolegacyresearch.com/three-pharma-companies-settle-alabama-opioid-suit-for-276-million/ 2022-04-21T04:01:00+00:00 https://biolegacyresearch.com/califf-outlines-fdas-newest-efforts-to-address-opioid-crisis/ 2022-04-21T04:01:00+00:00 https://biolegacyresearch.com/chicago-company-may-need-biologics-license-to-conduct-stem-cell-therapy/ 2022-04-21T04:01:00+00:00 https://biolegacyresearch.com/teva-and-medincell-receive-complete-response-letter-for-schizophrenia-drug/ 2022-04-21T04:01:00+00:00 https://biolegacyresearch.com/cdc-expert-panel-envisions-two-dose-booster-covid-19-series-plus-annual-booster/ 2022-04-21T04:01:00+00:00 https://biolegacyresearch.com/cder-outlines-its-regulatory-approach-to-nanomaterials-in-drug-products/ 2022-04-22T04:01:00+00:00 https://biolegacyresearch.com/u-s-drug-spending-increased-by-12-percent-in-2021-says-iqvia-report/ 2022-04-22T04:01:00+00:00 https://biolegacyresearch.com/fda-adcom-votes-nearly-unanimously-to-end-single-trial-approvals-for-pi3k-inhibitors/ 2022-04-22T04:01:00+00:00 https://biolegacyresearch.com/evusheld-cut-risk-of-covid-19-by-83-percent-in-high-risk-population/ 2022-04-22T04:01:00+00:00 https://biolegacyresearch.com/most-drugmakers-filed-timely-reports-on-postmarket-studies-in-2020-fda-says/ 2022-04-22T04:01:00+00:00 https://biolegacyresearch.com/who-issues-strong-recommendation-for-paxlovid-but-slams-pfizer-for-lack-of-transparency-in-dealmaking-regarding-the-drug/ 2022-04-22T22:05:54+00:00 https://biolegacyresearch.com/abbvie-sanofi-and-consegna-forge-new-partnerships/ 2022-04-22T22:07:32+00:00 https://biolegacyresearch.com/scynexis-touts-positive-interim-phase-3-data-for-antifungal-ibrexafungerp/ 2022-04-22T22:08:37+00:00 https://biolegacyresearch.com/fda-seeks-comments-on-pq-and-cms-data-exchanges/ 2022-04-22T22:09:43+00:00 https://biolegacyresearch.com/abaco-partners-gets-form-483-due-to-quality-control-testing-documentation-and-training/ 2022-04-22T22:15:31+00:00 https://biolegacyresearch.com/chmp-endorses-four-new-medicines-during-april-meeting-notes-withdrawal-of-aduhelm/ 2022-04-22T22:40:01+00:00 https://biolegacyresearch.com/axsome-therapeutics-expects-fda-will-reject-migraine-drug-for-approval/ 2022-04-25T21:20:18+00:00 https://biolegacyresearch.com/roches-oral-serd-candidate-for-advanced-breast-cancer-fails-in-trial/ 2022-04-25T22:10:32+00:00 https://biolegacyresearch.com/fda-to-ask-advisory-panel-to-reconsider-ardelyxs-kidney-drug/ 2022-04-25T22:14:23+00:00 https://biolegacyresearch.com/gileads-veklury-approved-for-pediatric-covid-19-patients-under-12/ 2022-04-25T22:46:29+00:00 https://biolegacyresearch.com/india-moves-to-reduce-dependence-on-foreign-apis/ 2022-04-25T22:47:55+00:00 https://biolegacyresearch.com/ema-puts-forth-prime-final-guidance-on-drugs-addressing-unmet-medical-needs/ 2022-04-25T22:50:09+00:00 https://biolegacyresearch.com/despite-confounders-biogen-claims-win-for-extended-tysabri-dosing-for-ms/ 2022-04-26T21:24:09+00:00 https://biolegacyresearch.com/shionogis-covid-19-treatment-rapidly-lowered-virus-counts/ 2022-04-26T21:25:24+00:00 https://biolegacyresearch.com/nearly-a-quarter-of-postmarket-trial-annual-reports-were-late-or-not-filed-in-fiscal-2020/ 2022-04-26T22:07:13+00:00 https://biolegacyresearch.com/fda-directors-defend-user-fee-reauthorization-as-senators-skewer-the-agency/ 2022-04-26T22:28:52+00:00 https://biolegacyresearch.com/renewed-push-for-march-in-rights-confronts-hhs-secretary-becerra/ 2022-04-26T22:30:39+00:00 https://biolegacyresearch.com/fda-issues-final-guidance-for-industry-on-submitting-safety-reports/ 2022-04-28T04:01:00+00:00 https://biolegacyresearch.com/janssen-follows-gilead-in-filing-federal-lawsuit-to-stop-counterfeit-versions-of-its-hiv-drugs/ 2022-04-28T04:01:00+00:00 https://biolegacyresearch.com/fda-warns-five-manufacturers-for-questionable-products/ 2022-04-28T04:01:00+00:00 https://biolegacyresearch.com/novartis-will-send-tislelizumab-application-to-regulators-for-esophageal-cancer/ 2022-04-28T04:01:00+00:00 https://biolegacyresearch.com/fda-calls-out-data-integrity-lapses-in-generic-drugs-forum/ 2022-04-28T04:01:00+00:00 https://biolegacyresearch.com/fda-commissioner-califf-outlines-fiscal-2023-fda-budget-requests-at-senate-hearing/ 2022-04-28T23:10:36+00:00 https://biolegacyresearch.com/fda-under-pressure-to-grant-swift-eua-for-modernas-vaccine-for-young-children/ 2022-04-28T23:11:49+00:00 https://biolegacyresearch.com/iqvia-issues-report-analyzing-unprecedented-speed-of-covid-19-vaccine-trials/ 2022-04-28T23:13:11+00:00 https://biolegacyresearch.com/amgen-faces-potential-7-1-billion-irs-fine-are-other-drugmakers-at-risk/ 2022-04-28T23:16:03+00:00 https://biolegacyresearch.com/fda-guidances-focus-on-trials-of-crohns-disease-ulcerative-colitis-drugs/ 2022-04-28T23:17:14+00:00 https://biolegacyresearch.com/lillys-tirzepatide-helps-shed-pounds-in-phase-3-study/ 2022-04-28T23:18:21+00:00 https://biolegacyresearch.com/big-three-covid-19-vaccine-maker-shareholders-vote-no-on-sharing-intellectual-property-with-lmics/ 2022-04-29T22:13:08+00:00 https://biolegacyresearch.com/fda-announces-dates-for-covid-19-vaccine-adcoms-though-no-full-applications-are-in-yet/ 2022-04-29T22:14:10+00:00 https://biolegacyresearch.com/novonordisks-once-weekly-insulin-controls-blood-sugar-as-well-as-daily-injections/ 2022-04-29T22:15:08+00:00 https://biolegacyresearch.com/gao-officials-testify-before-house-committee-on-ensuring-scientific-integrity/ 2022-04-29T22:43:07+00:00 https://biolegacyresearch.com/european-commission-approves-six-additional-indications-for-mercks-keytruda/ 2022-04-29T22:44:02+00:00 https://biolegacyresearch.com/crls-stymie-one-chinese-chemo-drug-grant-another-second-chance/ 2022-05-02T22:07:08+00:00 https://biolegacyresearch.com/fda-places-clinical-hold-on-vertexs-investigational-stem-cell-derived-therapy/ 2022-05-02T22:09:22+00:00 https://biolegacyresearch.com/aurolife-pharma-cites-cyberattack-for-missing-records/ 2022-05-02T22:11:19+00:00 https://biolegacyresearch.com/fda-releases-guidances-on-electronic-submission-of-individual-case-safety-reports/ 2022-05-02T23:07:00+00:00 https://biolegacyresearch.com/in-wake-of-repeated-rejections-biogen-abandons-its-flagship-ad-drug/ 2022-05-03T21:07:28+00:00 https://biolegacyresearch.com/fda-holds-fewer-adcoms-and-ignores-negative-votes-about-once-a-year-study-shows/ 2022-05-03T21:08:00+00:00 https://biolegacyresearch.com/cders-office-of-compliance-details-strides-covid-19-forced-it-to-make-in-2021/ 2022-05-03T21:12:00+00:00 https://biolegacyresearch.com/fda-declines-to-disqualify-minneapolis-investigators-and-irb-from-running-trials/ 2022-05-03T21:13:22+00:00 https://biolegacyresearch.com/tarsus-eyedrop-proves-mightier-than-mites/ 2022-05-03T22:14:43+00:00 https://biolegacyresearch.com/gsk-to-acquire-sierra-oncology-and-its-promising-blood-cancer-drug-for-1-9-billion/ 2022-05-03T22:37:47+00:00 https://biolegacyresearch.com/composition-for-covid-19-vaccine-for-2022-2023-season-must-be-decided-by-june-say-califf-woodcock-and-marks-in-jama-editorial/ 2022-05-04T22:15:51+00:00 https://biolegacyresearch.com/two-pharma-giants-link-up-with-amphista-on-protein-degradation-projects/ 2022-05-04T22:17:45+00:00 https://biolegacyresearch.com/contract-testing-lab-gets-warning-letter-for-falsified-data-other-cgmp-deviations/ 2022-05-04T22:18:58+00:00 https://biolegacyresearch.com/dupont-nutrition-hit-with-form-483-for-faulty-practices-and-missing-information/ 2022-05-04T22:20:29+00:00 https://biolegacyresearch.com/jj-files-lawsuit-against-saveonsp-for-allegedly-overbilling-for-its-medications/ 2022-05-06T04:01:00+00:00 https://biolegacyresearch.com/medicagos-plant-based-covid-19-vaccine-found-highly-effective-against-symptomatic-disease/ 2022-05-06T04:01:00+00:00 https://biolegacyresearch.com/fda-issues-warning-letter-to-iv-drug-compounder-in-california/ 2022-05-06T04:01:00+00:00 https://biolegacyresearch.com/astrazenecas-type-2-diabetes-drug-shows-promise-in-treating-early-heart-failure/ 2022-05-06T04:01:00+00:00 https://biolegacyresearch.com/fda-commissioner-califf-talks-about-his-many-goals-at-fda-in-jama/ 2022-05-06T04:01:00+00:00 https://biolegacyresearch.com/fda-limits-use-of-jjs-covid-19-vaccine/ 2022-05-06T04:01:00+00:00 https://biolegacyresearch.com/fda-counters-pfizers-ceo-on-second-paxlovid-course-after-rebound/ 2022-05-06T04:01:00+00:00 https://biolegacyresearch.com/industry-nervous-that-user-fee-reauthorization-legislation-will-get-bogged-down-with-extraneous-asks/ 2022-05-09T04:01:00+00:00 https://biolegacyresearch.com/novartis-sites-stop-manufacturing-nuclear-medicines-over-quality-problems/ 2022-05-09T04:01:00+00:00 https://biolegacyresearch.com/fda-yanks-accelerated-approval-for-bristol-myers-squibbs-celgenes-10-year-old-istodax-for-lymphoma/ 2022-05-09T04:01:00+00:00 https://biolegacyresearch.com/marinus-restarts-study-after-reformulating-problematic-drug/ 2022-05-09T04:01:00+00:00 https://biolegacyresearch.com/astrazenecas-ultomiris-delivers-in-phase-3-for-rare-autoimmune-disorder/ 2022-05-09T04:01:00+00:00 https://biolegacyresearch.com/astrazeneca-and-bayer-gain-priority-reviews-for-cancer-treatments/ 2022-05-09T04:01:00+00:00 https://biolegacyresearch.com/fda-open-to-less-than-50-percent-efficacy-in-covid-vaccines-for-smallest-kids/ 2022-05-09T22:25:33+00:00 https://biolegacyresearch.com/fda-offers-draft-guidance-on-product-quality-related-issues/ 2022-05-09T22:26:45+00:00 https://biolegacyresearch.com/fdas-cber-sets-its-planned-guidance-agenda-for-2022/ 2022-05-09T22:28:02+00:00 https://biolegacyresearch.com/fda-finds-switching-levothyroxine-generics-does-not-affect-hormone-levels/ 2022-05-09T22:29:16+00:00 https://biolegacyresearch.com/emas-prac-against-jazzs-defitelio-as-rare-liver-disease-preventive/ 2022-05-09T22:30:25+00:00 https://biolegacyresearch.com/ich-working-on-model-informed-drug-development-guideline-to-boost-trial-design/ 2022-05-09T22:31:48+00:00 https://biolegacyresearch.com/cber-plans-new-intermediate-pathway-for-cell-and-gene-therapies/ 2022-05-10T22:59:28+00:00 https://biolegacyresearch.com/in-11-6-billion-buyout-pfizer-acquires-biohaven-and-suite-of-migraine-meds/ 2022-05-10T23:00:02+00:00 https://biolegacyresearch.com/ohio-counties-jockey-for-878m-from-pharmacy-chains-as-opioid-trial-begins/ 2022-05-10T23:00:35+00:00 https://biolegacyresearch.com/safc-carlsbad-dinged-for-unsafe-biohazard-practices-alarm-problems/ 2022-05-10T23:02:26+00:00 https://biolegacyresearch.com/astrazeneca-sanofi-pooled-data-bolster-rsv-win-for-nirsevimab/ 2022-05-11T20:49:41+00:00 https://biolegacyresearch.com/fda-offers-advice-on-human-radiolabeled-mass-balance-studies/ 2022-05-11T20:50:49+00:00 https://biolegacyresearch.com/emergent-hid-quality-problems-with-covid-19-vaccines-new-report-shows/ 2022-05-11T21:52:51+00:00 https://biolegacyresearch.com/cder-launches-program-to-speed-development-of-rare-disease-treatments/ 2022-05-11T21:54:34+00:00 https://biolegacyresearch.com/roche-posts-another-tiragolumab-chemotherapy-flop/ 2022-05-11T21:56:00+00:00 https://biolegacyresearch.com/fda-encourages-veru-to-submit-eua-application-for-covid-19-therapy/ 2022-05-12T21:18:54+00:00 https://biolegacyresearch.com/abbvies-jak-inhibitor-rinvoq-scores-in-crohns-maintenance-therapy-trial/ 2022-05-12T21:33:26+00:00 https://biolegacyresearch.com/brigham-and-womens-gets-warning-letter-for-inadequate-aseptic-conditions/ 2022-05-12T21:42:04+00:00 https://biolegacyresearch.com/bipartisan-bill-would-clarify-orphan-drug-exclusivity/ 2022-05-12T22:23:39+00:00 https://biolegacyresearch.com/generic-versions-of-pfizers-covid-19-pill-to-cost-25-or-less-in-developing-world/ 2022-05-16T04:01:00+00:00 https://biolegacyresearch.com/allure-labs-cited-for-suspected-underreporting-of-problematic-otc-drug-events-testing-lapses/ 2022-05-16T04:01:00+00:00 https://biolegacyresearch.com/ucb-gets-another-roadblock-to-fda-approval-of-psoriasis-drug-this-time-a-crl/ 2022-05-16T04:01:00+00:00 https://biolegacyresearch.com/icer-says-no-to-molnupiravir-yes-to-paxlovid-and-fluvoxamine-for-outpatient-covid-treatment/ 2022-05-16T04:01:00+00:00 https://biolegacyresearch.com/gileads-lenacapavir-deeply-suppresses-hiv-load-in-multidrug-resistant-patients/ 2022-05-16T04:01:00+00:00 https://biolegacyresearch.com/astrazenecas-albuterol-budesonide-combo-asthma-drug-drops-flare-ups-in-study/ 2022-05-17T04:01:00+00:00 https://biolegacyresearch.com/fda-approves-eli-lillys-potential-blockbuster-in-type-2-diabetes/ 2022-05-17T04:01:00+00:00 https://biolegacyresearch.com/acella-pharmaceuticals-sued-over-recalled-thyroid-drug/ 2022-05-17T04:01:00+00:00 https://biolegacyresearch.com/bridgebio-sells-coveted-priority-review-voucher-for-110m-to-undisclosed-buyer/ 2022-05-17T04:01:00+00:00 https://biolegacyresearch.com/bms-opdivo-and-yervoy-combination-fails-to-meet-key-endpoint-in-urothelial-cancer/ 2022-05-17T04:01:00+00:00 https://biolegacyresearch.com/fda-oks-booster-of-pfizer-biontech-covid-19-vaccine-for-kids-five-to-11/ 2022-05-17T21:32:43+00:00 https://biolegacyresearch.com/fda-says-no-to-generic-antidepressant-fluvoxamine-as-a-covid-19-treatment/ 2022-05-17T22:27:13+00:00 https://biolegacyresearch.com/fda-lifts-hold-on-gilead-sciences-investigational-hiv-drug-lenacapavir/ 2022-05-17T22:28:22+00:00 https://biolegacyresearch.com/fda-issues-final-guidance-on-assessing-user-fees-under-gdufa-ii/ 2022-05-17T22:29:33+00:00 https://biolegacyresearch.com/fda-updates-oos-testing-principles-in-revised-final-guidance/ 2022-05-17T22:30:54+00:00 https://biolegacyresearch.com/senate-committee-releases-draft-user-fee-bill-as-house-votes-to-send-its-version-to-the-floor/ 2022-05-18T22:00:40+00:00 https://biolegacyresearch.com/focus-label-design-on-preventing-medication-errors-fda-final-guidance-tells-drugmakers/ 2022-05-18T22:01:52+00:00 https://biolegacyresearch.com/surrogate-endpoints-fewer-trials-continue-to-back-novel-drug-approvals/ 2022-05-18T22:03:05+00:00 https://biolegacyresearch.com/asthma-drug-developers-obstructed-generics-study-finds/ 2022-05-18T22:04:28+00:00 https://biolegacyresearch.com/phrma-wins-as-federal-judge-tosses-out-2020-medicaid-best-price-requirement/ 2022-05-19T21:22:00+00:00 https://biolegacyresearch.com/nasem-calls-for-action-by-fda-nih-to-improve-trial-diversity/ 2022-05-19T21:23:21+00:00 https://biolegacyresearch.com/house-subcommittee-quizzes-califf-on-new-role-for-woodcock-status-of-foreign-inspections-in-budget-hearing/ 2022-05-19T21:38:02+00:00 https://biolegacyresearch.com/cdc-panel-recommends-booster-doses-in-children-age-five-to-11/ 2022-05-19T22:16:41+00:00 https://biolegacyresearch.com/states-medical-groups-file-briefs-supporting-hhs-in-legal-battle-over-340b-drug-discount-program/ 2022-05-19T22:43:23+00:00 https://biolegacyresearch.com/senators-press-ftc-to-investigate-the-role-of-pbms-in-insulin-pricing/ 2022-05-20T21:43:00+00:00 https://biolegacyresearch.com/ema-expert-panel-recommends-nine-new-medicines-during-may-meeting/ 2022-05-20T21:44:16+00:00 https://biolegacyresearch.com/fda-guidance-urges-drugmakers-to-use-risk-management-plans-to-protect-the-supply-chain/ 2022-05-20T22:13:32+00:00 https://biolegacyresearch.com/rocket-reports-100-percent-survival-in-rare-pediatric-immunodeficiency-trial/ 2022-05-20T22:14:00+00:00 https://biolegacyresearch.com/thyroid-api-manufacturer-gets-warning-letter-for-validation-conformance-lapses/ 2022-05-20T22:15:59+00:00 https://biolegacyresearch.com/fda-proposes-new-rules-for-medical-gases/ 2022-05-20T22:40:51+00:00 https://biolegacyresearch.com/biohaven-wont-give-up-despite-falling-short-on-phase-3-for-spinocerebellar-ataxia/ 2022-05-24T04:01:00+00:00 https://biolegacyresearch.com/ema-recommends-suspending-100-generic-meds-after-data-irregularities-found-in-bioequivalence-studies/ 2022-05-24T04:01:00+00:00 https://biolegacyresearch.com/fda-approves-sanofi-and-regenerons-dupixent-for-eosinophilic-esophagitis/ 2022-05-24T04:01:00+00:00 https://biolegacyresearch.com/celgenes-chemotherapy-approved-for-rare-form-of-leukemia-in-pediatric-population/ 2022-05-24T04:01:00+00:00 https://biolegacyresearch.com/fda-warns-colorful-products-for-quality-control-lapses/ 2022-05-24T04:01:00+00:00 https://biolegacyresearch.com/lilly-pfizer-showcase-positive-pivotal-data-in-ulcerative-colitis-trials/ 2022-05-24T21:55:51+00:00 https://biolegacyresearch.com/fda-draft-guidance-gives-more-direction-for-developing-antibacterial-drugs-for-unmet-needs/ 2022-05-24T22:34:23+00:00 https://biolegacyresearch.com/vanda-sues-fda-for-capricious-denial-of-fast-track-status/ 2022-05-24T22:36:08+00:00 https://biolegacyresearch.com/federal-judge-rules-against-gilead-in-lexiscan-generic-case/ 2022-05-24T22:38:00+00:00 https://biolegacyresearch.com/nirogacestat-springworks-gamma-secretase-inhibitor-scores-in-phase-3-desmoid-tumor-trial/ 2022-05-25T21:12:44+00:00 https://biolegacyresearch.com/blockbusters-accelerated-approval-drugs-get-most-fda-cleared-formulations/ 2022-05-25T22:23:47+00:00 https://biolegacyresearch.com/verrica-draws-second-complete-response-letter-for-manufacturing-deficiencies/ 2022-05-25T22:26:03+00:00 https://biolegacyresearch.com/fda-issues-small-entity-guidance-for-importing-prescription-drugs-from-canada/ 2022-05-25T22:27:36+00:00 https://biolegacyresearch.com/ema-publishes-revised-guideline-on-evaluating-antibacterial-drugs/ 2022-05-25T22:30:22+00:00 https://biolegacyresearch.com/surging-oncology-research-yields-big-approval-dividends-and-lucrative-payoffs-study-says/ 2022-05-26T21:01:04+00:00 https://biolegacyresearch.com/fda-issues-final-guidance-on-developing-gnrh-analogues-for-advanced-prostate-cancer/ 2022-05-26T21:02:38+00:00 https://biolegacyresearch.com/form-483-docks-clinical-formula-for-inadequate-quality-and-laboratory-controls/ 2022-05-26T21:36:42+00:00 https://biolegacyresearch.com/cantwell-grassley-introduce-senate-bill-to-control-pbms-pricing-practices/ 2022-05-26T22:28:01+00:00 https://biolegacyresearch.com/teva-and-allergan-reach-161-5-million-opioid-settlement-with-west-virginia/ 2022-05-26T22:34:28+00:00 https://biolegacyresearch.com/hhs-kills-the-trump-rule-requiring-agencies-to-reassess-regulations-every-10-years/ 2022-05-27T19:32:00+00:00 https://biolegacyresearch.com/topline-data-support-nda-for-zealands-treatment-for-rare-childhood-hypoglycemia-disorder/ 2022-05-27T19:33:00+00:00 https://biolegacyresearch.com/senators-push-fda-and-pto-to-coordinate-better-on-drug-patents-that-could-delay-generics/ 2022-05-27T20:26:00+00:00 https://biolegacyresearch.com/senate-user-fee-package-addresses-accelerated-approval-rare-disease-issues/ 2022-05-27T20:41:00+00:00 https://biolegacyresearch.com/gsk-buys-affinivax-in-3-3b-deal-nets-two-vaccine-candidates-and-novel-technology/ 2022-05-31T20:56:40+00:00 https://biolegacyresearch.com/jj-sues-aurobindo-pharma-over-proposed-generic-prostate-cancer-drug/ 2022-05-31T21:25:09+00:00 https://biolegacyresearch.com/world-health-organization-resolves-to-improve-clinical-trials-globally/ 2022-05-31T21:26:56+00:00 https://biolegacyresearch.com/clinical-hold-snags-sanofis-otc-cialis-plans/ 2022-05-31T21:37:29+00:00 https://biolegacyresearch.com/ftc-deluged-with-more-than-24000-comments-about-pbms-effect-on-patients-and-payers/ 2022-06-02T04:01:00+00:00 https://biolegacyresearch.com/in-latest-salvo-over-dueling-cholesterol-fighting-antibodies-regeneron-files-new-antitrust-suit-against-amgen/ 2022-06-02T04:01:00+00:00 https://biolegacyresearch.com/two-weeks-of-sage-therapeutics-zuranolone-improves-postpartum-depression/ 2022-06-02T04:01:00+00:00 https://biolegacyresearch.com/fda-withdraws-ukoniq-approval-tg-therapeutics-initiates-voluntary-market-withdrawal/ 2022-06-02T04:01:00+00:00 https://biolegacyresearch.com/regeneron-to-buy-out-sanofis-stake-in-jointly-developed-libtayo/ 2022-06-02T22:08:51+00:00 https://biolegacyresearch.com/hoping-for-an-alzheimers-win-scineuro-rescues-cardiovascular-drug-flop-from-gsk-dustbin/ 2022-06-02T22:10:51+00:00 https://biolegacyresearch.com/opdivo-wins-two-additional-approvals-for-esophageal-cancer-chemo-regimens/ 2022-06-02T22:12:17+00:00 https://biolegacyresearch.com/nephron-voluntarily-recalls-2m-doses-after-fda-inspection-finds-lack-of-sterility/ 2022-06-02T22:18:47+00:00 https://biolegacyresearch.com/pfizer-biontech-contest-alnylams-patent-claims-over-covid-19-vaccine-technology/ 2022-06-02T22:25:08+00:00 https://biolegacyresearch.com/jjs-abbvies-imbruvica-significantly-curtails-rare-lymphoma-progression/ 2022-06-06T04:01:00+00:00 https://biolegacyresearch.com/bms-to-buy-oncology-focused-turning-point-for-4-1b-netting-three-breakthrough-therapy-candidates/ 2022-06-06T04:01:00+00:00 https://biolegacyresearch.com/fda-committee-to-review-novavaxs-eua-application-for-its-covid-19-vaccine/ 2022-06-06T04:01:00+00:00 https://biolegacyresearch.com/immune-modulators-used-in-rheumatoid-arthritis-also-cut-covid-19-mortality/ 2022-06-06T04:01:00+00:00 https://biolegacyresearch.com/asco-highlights-breast-cancer-treatments-by-astrazeneca-gilead/ 2022-06-07T04:01:00+00:00 https://biolegacyresearch.com/hackers-make-off-with-novartis-data-but-company-denies-major-breach/ 2022-06-07T04:01:00+00:00 https://biolegacyresearch.com/gsks-jemperli-eliminates-rectal-tumors-in-study/ 2022-06-07T04:01:00+00:00 https://biolegacyresearch.com/otc-drugmaker-in-mexico-gets-warning-letter-for-improper-listing/ 2022-06-07T04:01:00+00:00 https://biolegacyresearch.com/jj-to-drop-emergent-after-mutual-claims-of-contract-breach/ 2022-06-08T04:01:00+00:00 https://biolegacyresearch.com/novartis-chemo-combo-pulls-impressive-numbers-in-tough-to-treat-pediatric-brain-tumors/ 2022-06-08T04:01:00+00:00 https://biolegacyresearch.com/former-eli-lilly-employee-files-lawsuit-alleging-manufacturing-problems-at-n-j-facility/ 2022-06-08T04:01:00+00:00 https://biolegacyresearch.com/fda-advisory-committee-recommends-novavaxs-covid-19-vaccine/ 2022-06-08T04:01:00+00:00 https://biolegacyresearch.com/amid-controversy-ftc-votes-to-investigate-large-pbms/ 2022-06-08T22:08:17+00:00 https://biolegacyresearch.com/genentech-files-suit-against-tanvex-biopharma-for-alleged-infringement-of-herceptin-patents/ 2022-06-08T22:09:43+00:00 https://biolegacyresearch.com/mercks-covid-19-pill-cuts-risk-of-death-and-hastens-recovery/ 2022-06-08T22:17:00+00:00 https://biolegacyresearch.com/opdp-raps-altheras-promotional-pamphlet-for-cholesterol-drug/ 2022-06-08T22:27:38+00:00 https://biolegacyresearch.com/fda-form-483-cites-nephron-pharmaceuticals-for-unsanitary-practices-lack-of-recordkeeping/ 2022-06-08T22:28:42+00:00 https://biolegacyresearch.com/fda-could-require-more-data-on-generic-combo-products-user-interfaces-agency-document-says/ 2022-06-10T04:01:00+00:00 https://biolegacyresearch.com/evusheld-protected-unvaccinated-high-risk-patients-from-covid-19-progression-or-death/ 2022-06-10T04:01:00+00:00 https://biolegacyresearch.com/house-passes-user-fee-reauthorization-bill-senate-mark-up-slated-for-next-week/ 2022-06-10T04:01:00+00:00 https://biolegacyresearch.com/launch-price-of-new-drugs-rising-by-20-percent-annually-says-study/ 2022-06-10T04:01:00+00:00 https://biolegacyresearch.com/fda-expert-panel-gives-thumbs-up-to-second-bluebird-bio-gene-therapy/ 2022-06-10T21:57:51+00:00 https://biolegacyresearch.com/federal-court-narrows-price-fixing-lawsuit-against-generic-drugmakers/ 2022-06-10T22:07:25+00:00 https://biolegacyresearch.com/cber-aims-to-resume-normal-operations-in-2023/ 2022-06-10T22:49:31+00:00 https://biolegacyresearch.com/eywa-pharma-gets-483-for-inadequate-investigation-validation-changes-and-cleaning-procedures/ 2022-06-10T22:50:32+00:00 https://biolegacyresearch.com/ema-recommends-withdrawal-of-obesity-drugs-containing-amfepramone/ 2022-06-13T21:40:29+00:00 https://biolegacyresearch.com/aduhelm-sees-yet-another-loss-with-biogen-pulling-its-application-in-canada/ 2022-06-13T21:52:07+00:00 https://biolegacyresearch.com/extended-trial-data-show-continued-benefit-of-gene-treatment-for-blood-diseases/ 2022-06-13T22:05:52+00:00 https://biolegacyresearch.com/fda-supports-expanded-euas-for-pfizer-biontech-and-moderna-pediatric-covid-19-vaccines/ 2022-06-13T22:35:58+00:00 https://biolegacyresearch.com/fda-vaccine-committee-recommends-moderna-vaccine-for-two-pediatric-age-groups/ 2022-06-14T22:31:07+00:00 https://biolegacyresearch.com/fda-seeks-comment-on-revised-ich-quality-risk-management-guideline/ 2022-06-14T22:32:15+00:00 https://biolegacyresearch.com/senate-help-committee-advances-fda-user-fee-bill/ 2022-06-14T23:42:00+00:00 https://biolegacyresearch.com/rare-diseases-rwd-supply-chain-headline-cders-priority-list/ 2022-06-14T23:48:35+00:00 https://biolegacyresearch.com/senate-committee-passes-importation-amendment-to-user-fee-bill-industry-objects/ 2022-06-15T22:39:09+00:00 https://biolegacyresearch.com/fda-advisory-panel-recommends-moderna-and-pfizer-vaccines-for-children-six-months-and-older/ 2022-06-15T22:40:37+00:00 https://biolegacyresearch.com/icer-amylyxs-proposed-als-drug-needs-to-be-much-cheaper-than-approved-radicava/ 2022-06-15T22:41:50+00:00 https://biolegacyresearch.com/covid-continued-to-slow-inspection-activities-in-fy-2021-fda-says/ 2022-06-15T22:42:53+00:00 https://biolegacyresearch.com/supreme-court-sides-with-hospitals-in-dispute-over-340b-drug-discount-program/ 2022-06-16T21:36:56+00:00 https://biolegacyresearch.com/who-recommends-three-vaccines-for-monkeypox-as-cases-climb-globally/ 2022-06-16T21:51:19+00:00 https://biolegacyresearch.com/arcadia-hopes-to-convince-fda-to-expand-nuzpladizs-indication/ 2022-06-16T22:08:41+00:00 https://biolegacyresearch.com/roche-pulls-plug-on-crenezumab-after-another-alzheimers-disease-trial-disappointment/ 2022-06-16T22:09:55+00:00 https://biolegacyresearch.com/acadia-hopes-to-convince-fda-to-expand-nuzpladizs-indication/ 2022-06-17T04:01:00+00:00 https://biolegacyresearch.com/acadia-hopes-to-convince-fda-to-expand-nuplazids-indication/ 2022-06-17T04:01:00+00:00 https://biolegacyresearch.com/wto-reaches-ip-sharing-agreement-pharma-industry-and-ngos-not-happy/ 2022-06-17T20:51:22+00:00 https://biolegacyresearch.com/ftc-targets-illegal-rebates-by-drugmakers-alleged-bribes-to-pbms/ 2022-06-17T21:29:34+00:00 https://biolegacyresearch.com/fda-grants-eua-to-modernas-covid-19-vaccine-for-children-and-updates-pfizer-vaccine-eua/ 2022-06-17T21:30:38+00:00 https://biolegacyresearch.com/house-appropriations-committee-to-consider-10-percent-budget-increase-for-the-fda/ 2022-06-17T21:37:43+00:00 https://biolegacyresearch.com/mark-cubans-online-generic-drug-company-could-save-medicare-billions-study-shows/ 2022-06-21T20:53:29+00:00 https://biolegacyresearch.com/astrazeneca-will-take-positive-phase-3-interim-data-on-attr-drug-to-fda/ 2022-06-21T21:36:45+00:00 https://biolegacyresearch.com/user-fee-reauthorization-accelerated-approvals-discussed-at-dia-annual-meeting/ 2022-06-21T23:02:29+00:00 https://biolegacyresearch.com/enanta-files-suit-against-pfizer-for-patent-violation-in-paxlovid-development/ 2022-06-23T04:01:00+00:00 https://biolegacyresearch.com/glicernas-industriales-refuses-fda-inspection-gets-warning-letter-and-import-alert/ 2022-06-23T04:01:00+00:00 https://biolegacyresearch.com/ptc-finally-gets-positive-results-in-a-study-on-duchenne-drug-translarna/ 2022-06-23T04:01:00+00:00 https://biolegacyresearch.com/cber-updates-its-guidance-agenda-for-2022/ 2022-06-23T04:01:00+00:00 https://biolegacyresearch.com/house-appropriations-committee-votes-yes-on-10-percent-increase-for-fda-in-fy-23/ 2022-06-23T22:57:14+00:00 https://biolegacyresearch.com/fda-specifies-criteria-for-rescinding-breakthrough-designation/ 2022-06-23T22:58:05+00:00 https://biolegacyresearch.com/leader-schumer-says-insulin-cost-control-bill-headed-to-senate-floor-soon/ 2022-06-23T22:59:05+00:00 https://biolegacyresearch.com/fda-stopped-record-number-of-drug-shortages-last-year/ 2022-06-23T23:00:01+00:00 https://biolegacyresearch.com/fda-inspection-backlogs-are-hitting-biosimilars-particularly-hard/ 2022-06-23T23:00:52+00:00 https://biolegacyresearch.com/fda-expands-cross-contamination-guidance-to-cover-non-penicillin-beta-lactam-drugs/ 2022-06-27T04:01:00+00:00 https://biolegacyresearch.com/fda-places-clinical-hold-on-sareptas-duchenne-drug-candidate/ 2022-06-27T04:01:00+00:00 https://biolegacyresearch.com/fda-unveils-five-year-plan-for-rare-neurodegenerative-disease-research/ 2022-06-27T04:01:00+00:00 https://biolegacyresearch.com/chmp-recommends-nine-new-drugs-in-latest-monthly-meeting/ 2022-06-27T04:01:00+00:00 https://biolegacyresearch.com/brookings-usc-suggests-ways-to-boost-generic-competition/ 2022-06-28T04:01:00+00:00 https://biolegacyresearch.com/fda-proposes-rule-to-improve-access-to-nonprescription-drugs/ 2022-06-28T04:01:00+00:00 https://biolegacyresearch.com/fdas-spring-regulatory-agenda-adds-proposed-rule-on-compounded-drug-distribution/ 2022-06-28T04:01:00+00:00 https://biolegacyresearch.com/gilead-settles-with-second-florida-clinic-in-hiv-prep-drug-counterfeit-case/ 2022-06-28T04:01:00+00:00 https://biolegacyresearch.com/speros-fast-tracked-antibiotic-drug-candidate-for-complicated-utis-hits-snag/ 2022-06-28T21:40:45+00:00 https://biolegacyresearch.com/ucb-becomes-9th-company-reprimanded-by-hrsa-for-limiting-340b-program-participation/ 2022-06-28T21:42:27+00:00 https://biolegacyresearch.com/uveitis-prompts-partial-clinical-hold-on-nuvation-bio-cancer-drug/ 2022-06-28T21:43:48+00:00 https://biolegacyresearch.com/fda-expert-panel-recommends-omicron-updated-covid-19-booster-shots/ 2022-06-28T22:18:48+00:00 https://biolegacyresearch.com/one-hundred-lawmakers-urge-hhs-to-help-lower-prescription-drug-prices/ 2022-06-30T04:01:00+00:00 https://biolegacyresearch.com/sanofi-drops-monthly-out-of-pocket-insulin-cost-to-35-for-uninsured-patients-amid-controversy-over-insulin-prices/ 2022-06-30T04:01:00+00:00 https://biolegacyresearch.com/fda-posts-final-guidances-on-adjuvant-therapies-for-renal-cell-and-bladder-cancer/ 2022-06-30T04:01:00+00:00 https://biolegacyresearch.com/fda-releases-guidance-on-fit-for-purpose-clinical-outcome-assessments/ 2022-06-30T04:01:00+00:00 https://biolegacyresearch.com/fda-places-clinical-hold-on-sanofis-btk-inhibitor-in-ms-and-myasthenia-gravis-trials/ 2022-06-30T21:22:26+00:00 https://biolegacyresearch.com/novartis-restarts-production-at-its-millburn-n-j-facility/ 2022-06-30T21:23:30+00:00 https://biolegacyresearch.com/fagrons-api-facility-in-minnesota-gets-fda-warning-letter/ 2022-06-30T21:24:36+00:00 https://biolegacyresearch.com/pfizer-seeks-full-fda-approval-for-oral-covid-19-therapy-paxlovid/ 2022-06-30T21:44:37+00:00 https://biolegacyresearch.com/copiktra-may-increase-risk-of-death-serious-side-effects-fda-warns/ 2022-07-01T19:43:00+00:00 https://biolegacyresearch.com/pharma-industry-spends-more-on-lobbying-than-any-other-industry-report-shows/ 2022-07-01T19:44:35+00:00 https://biolegacyresearch.com/i3-pharmaceuticals-draws-form-483-over-quality-control-lapses/ 2022-07-01T19:45:48+00:00 https://biolegacyresearch.com/fda-approval-doesnt-substantially-increase-access-to-novel-treatments-for-some-populations-study/ 2022-07-01T20:34:02+00:00 https://biolegacyresearch.com/astrazeneca-to-buy-teneotwo-netting-promising-lymphoma-candidate/ 2022-07-06T04:01:00+00:00 https://biolegacyresearch.com/fda-grants-amylyx-a-second-hearing-for-rejected-als-drug/ 2022-07-06T04:01:00+00:00 https://biolegacyresearch.com/federal-judge-finds-big-drug-distributors-are-not-to-blame-for-opioid-epidemic/ 2022-07-06T04:01:00+00:00 https://biolegacyresearch.com/fda-releases-draft-supply-chain-guidances-on-trading-partners-and-electronic-reporting/ 2022-07-06T04:01:00+00:00 https://biolegacyresearch.com/jury-finds-endo-pharmaceuticals-pay-for-delay-deal-didnt-break-antitrust-laws/ 2022-07-06T21:22:13+00:00 https://biolegacyresearch.com/curevac-goes-after-biontech-claiming-patent-infringement-by-comirnatys-mrna-underpinnings/ 2022-07-06T21:23:46+00:00 https://biolegacyresearch.com/skyhawk-teams-with-sanofi-on-oncology-and-immunology-targets-in-deal-worth-potentially-2-billion/ 2022-07-06T21:26:03+00:00 https://biolegacyresearch.com/fda-revises-eua-to-allow-pharmacists-to-prescribe-pfizers-paxlovid/ 2022-07-06T21:36:21+00:00 https://biolegacyresearch.com/senate-democrats-propose-much-anticipated-legislation-allowing-medicare-to-negotiate-drug-prices/ 2022-07-07T22:19:23+00:00 https://biolegacyresearch.com/policy-experts-pallones-bill-would-give-fda-more-control-over-fast-tracked-drugs/ 2022-07-07T22:21:00+00:00 https://biolegacyresearch.com/biogen-eisai-gains-accelerated-approval-pathway-for-antiamyloid-antibody-lecanemab/ 2022-07-07T22:23:17+00:00 https://biolegacyresearch.com/republicans-seek-to-slow-collins-shaheen-insulin-price-capping-bill/ 2022-07-08T21:51:18+00:00 https://biolegacyresearch.com/use-of-continuous-manufacturing-leads-to-faster-approvals-fda-study-says/ 2022-07-08T21:52:33+00:00 https://biolegacyresearch.com/bms-settles-patent-dispute-with-alembic-over-blockbuster-revlimid/ 2022-07-08T22:03:05+00:00 https://biolegacyresearch.com/fda-patent-office-will-work-together-to-protect-low-cost-drugs/ 2022-07-08T22:14:08+00:00 https://biolegacyresearch.com/novo-nordisk-touts-potential-hemophilia-treatment-at-london-meeting/ 2022-07-11T22:08:39+00:00 https://biolegacyresearch.com/perrigo-applies-to-fda-for-rx-to-otc-switch-for-49-year-old-progestin-only-birth-control-pill/ 2022-07-11T22:34:06+00:00 https://biolegacyresearch.com/drug-groups-press-fda-for-transparency-on-quality-metrics-reporting-program/ 2022-07-11T22:35:23+00:00 https://biolegacyresearch.com/robert-califf-sounds-alarm-if-user-fees-arent-reauthorized-quickly/ 2022-07-12T22:48:37+00:00 https://biolegacyresearch.com/new-bill-would-force-fda-to-finalize-15-year-old-rule-on-drug-advertising/ 2022-07-12T22:50:33+00:00 https://biolegacyresearch.com/catalyst-jacobus-settle-patent-dispute-over-lems-drug-ruzurgi/ 2022-07-12T22:54:23+00:00 https://biolegacyresearch.com/zydus-hit-with-cancer-drug-patent-suit-over-xtandi/ 2022-07-12T22:57:00+00:00 https://biolegacyresearch.com/judge-approves-viatris-settlement-of-epipen-lawsuit-for-264-million/ 2022-07-13T21:30:20+00:00 https://biolegacyresearch.com/at-11th-hour-allergan-and-teva-settle-with-san-francisco-for-54m-over-opioid-crisis/ 2022-07-13T21:32:32+00:00 https://biolegacyresearch.com/fda-authorizes-novavaxs-covid-19-vaccine/ 2022-07-13T21:42:17+00:00 https://biolegacyresearch.com/sanofi-touts-positive-phase-3-data-for-two-hemophilia-treatments/ 2022-07-13T21:43:23+00:00 https://biolegacyresearch.com/merck-orion-join-forces-to-develop-novel-treatment-for-prostate-cancer/ 2022-07-13T21:44:26+00:00 https://biolegacyresearch.com/ifus-must-match-fda-approved-prescribing-information-fda-says/ 2022-07-15T04:01:00+00:00 https://biolegacyresearch.com/fda-defers-action-on-beigene-novartis-checkpoint-inhibitor-citing-inspection-problems/ 2022-07-15T04:01:00+00:00 https://biolegacyresearch.com/dupixent-improves-lab-markers-of-eosinophilic-esophagitis-in-children/ 2022-07-15T04:01:00+00:00 https://biolegacyresearch.com/teva-appeals-skinny-labeling-case-to-supreme-court/ 2022-07-15T04:01:00+00:00 https://biolegacyresearch.com/icer-novo-nordisks-wegovy-needs-significant-discount-to-be-cost-effective/ 2022-07-18T04:01:00+00:00 https://biolegacyresearch.com/pet-drugmaker-draws-fda-form-483-for-quality-issues/ 2022-07-18T04:01:00+00:00 https://biolegacyresearch.com/nineteen-days-ahead-of-deadline-to-pass-user-fee-reauthorization-sen-burr-introduces-version-of-the-bill-stripped-of-all-amendments-and-riders/ 2022-07-18T04:01:00+00:00 https://biolegacyresearch.com/senates-proposed-affordable-insulin-bill-would-cost-23-billion-over-10-years/ 2022-07-18T04:01:00+00:00 https://biolegacyresearch.com/lilly-and-triastek-to-collaborate-on-3d-printing-for-gi-tract-drugs/ 2022-07-18T22:34:38+00:00 https://biolegacyresearch.com/roche-unveils-positive-phase-3-data-in-breast-cancer-trial/ 2022-07-18T22:35:58+00:00 https://biolegacyresearch.com/novo-nordisk-sues-biocon-for-patent-infringement-over-blockbuster-weight-loss-and-diabetes-drugs/ 2022-07-18T22:37:40+00:00 https://biolegacyresearch.com/lawmakers-push-biden-administration-to-penalize-drugmakers-limiting-340b-discounts/ 2022-07-19T22:07:02+00:00 https://biolegacyresearch.com/heart-drug-vascepa-may-not-be-as-effective-as-previously-believed-analysis-shows/ 2022-07-19T22:08:47+00:00 https://biolegacyresearch.com/mercks-lynparza-flops-in-phase-3-colorectal-cancer-study/ 2022-07-19T22:10:17+00:00 https://biolegacyresearch.com/ultragenyx-acquires-genetx-netting-promising-angelman-syndrome-candidate/ 2022-07-19T22:12:07+00:00 https://biolegacyresearch.com/hematology-cell-therapy-market-faces-overload-report-says/ 2022-07-21T04:01:00+00:00 https://biolegacyresearch.com/mercks-keytruda-stumbles-in-phase-3-head-and-neck-cancer-trial/ 2022-07-21T04:01:00+00:00 https://biolegacyresearch.com/dose-banded-product-labeling-needs-weight-based-calculation-instructions-guidance-says/ 2022-07-21T04:01:00+00:00 https://biolegacyresearch.com/api-company-bioiberica-slapped-with-warning-letter-for-contamination-and-process-issues/ 2022-07-21T04:01:00+00:00 https://biolegacyresearch.com/impax-laboratories-to-pay-145-million-settlement-over-generic-opioid/ 2022-07-21T21:34:00+00:00 https://biolegacyresearch.com/roche-scuttles-five-clinical-trials-for-major-diseases/ 2022-07-21T22:00:31+00:00 https://biolegacyresearch.com/novartis-gives-up-on-tislelizumab-as-monotherapy-for-nsclc/ 2022-07-21T22:13:29+00:00 https://biolegacyresearch.com/ema-invites-comment-on-draft-ich-drug-interaction-studies-guideline/ 2022-07-21T22:25:01+00:00 https://biolegacyresearch.com/global-crackdown-of-online-pharmacies-seizes-illicit-medicines-from-36-organized-crime-groups/ 2022-07-22T22:31:08+00:00 https://biolegacyresearch.com/fda-to-use-remote-regulatory-assessment-tools-beyond-pandemic/ 2022-07-25T04:01:00+00:00 https://biolegacyresearch.com/failure-to-pass-user-fee-reauthorization-could-cost-fda-2-billion/ 2022-07-25T04:01:00+00:00 https://biolegacyresearch.com/fda-proposes-rule-to-standardize-national-drug-code-format/ 2022-07-25T04:01:00+00:00